A benign epithelial tumor with a glandular organization.
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.
Tumors or cancer of the human BREAST.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING).
An amino acid that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as CREATININE in the urine.
Stable elementary particles having the smallest known positive charge, found in the nuclei of all elements. The proton mass is less than that of a neutron. A proton is the nucleus of the light hydrogen atom, i.e., the hydrogen ion.
One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.
An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).
An operation for retinal detachment which reduces the size of the globe by indenting the sclera so that it approximates the retina.
Removal of the whole or part of the vitreous body in treating endophthalmitis, diabetic retinopathy, retinal detachment, intraocular foreign bodies, and some types of glaucoma.
A method of stopping internal bleeding or blood flow, or the closure of a wound or body cavity, achieved by applying pressure or introducing an absorbent liquid, gel, or tampon.
Vitreoretinal membrane shrinkage or contraction secondary to the proliferation of primarily retinal pigment epithelial cells and glial cells, particularly fibrous astrocytes, followed by membrane formation. The formation of fibrillar collagen and cellular proliferation appear to be the basis for the contractile properties of the epiretinal and vitreous membranes.
Detachment of the corpus vitreum (VITREOUS BODY) from its normal attachments, especially the retina, due to shrinkage from degenerative or inflammatory conditions, trauma, myopia, or senility.
The transparent, semigelatinous substance that fills the cavity behind the CRYSTALLINE LENS of the EYE and in front of the RETINA. It is contained in a thin hyaloid membrane and forms about four fifths of the optic globe.
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
Heterodimeric transcription factors containing a DNA-binding alpha subunits, (CORE BINDING FACTOR ALPHA SUBUNITS), along with a non-DNA-binding beta subunits, CORE BINDING FACTOR BETA SUBUNIT. Core Binding Factor regulates GENETIC TRANSCRIPTION of a variety of GENES involved primarily in CELL DIFFERENTIATION and CELL CYCLE progression.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Myosin type II isoforms found in smooth muscle.
The larger subunits of MYOSINS. The heavy chains have a molecular weight of about 230 kDa and each heavy chain is usually associated with a dissimilar pair of MYOSIN LIGHT CHAINS. The heavy chains possess actin-binding and ATPase activity.
Progenitor cells from which all blood cells derive.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Laboratory techniques that involve the in-vitro synthesis of many copies of DNA or RNA from one original template.
Methods for using more than one primer set in a polymerase chain reaction to amplify more than one segment of the target DNA sequence in a single reaction.
The number of copies of a given gene present in the cell of an organism. An increase in gene dosage (by GENE DUPLICATION for example) can result in higher levels of gene product formation. GENE DOSAGE COMPENSATION mechanisms result in adjustments to the level GENE EXPRESSION when there are changes or differences in gene dosage.
Stretches of genomic DNA that exist in different multiples between individuals. Many copy number variations have been associated with susceptibility or resistance to disease.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
An enzyme catalyzing the transfer of a phosphate group from 3-phospho-D-glycerate in the presence of ATP to yield 3-phospho-D-glyceroyl phosphate and ADP. EC 2.7.2.3.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Very large BONE MARROW CELLS which release mature BLOOD PLATELETS.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
An abnormal response to a stimulus applied to the sensory components of the nervous system. This may take the form of increased, decreased, or absent reflexes.
Individuals enrolled in a school or formal educational program.
An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER.
Individuals enrolled in a school of medicine or a formal educational program in medicine.
Undergraduate education programs for second- , third- , and fourth-year students in health sciences in which the students receive clinical training and experience in teaching hospitals or affiliated health centers.
The ability to acquire general or special types of knowledge or skill.
A pair of nuclei and associated gray matter in the interpeduncular space rostral to the posterior perforated substance in the posterior hypothalamus.

Postoperative magnetic resonance imaging after acoustic neuroma surgery: influence of packing materials in the drilled internal auditory canal on assessment of residual tumor. (1/1193)

Serial magnetic resonance (MR) images taken after acoustic neuroma surgery were analyzed to evaluate the pattern and timing of postoperative contrast enhancement in 22 patients who underwent acoustic neuroma removal via the suboccipital transmeatal approach. The opened internal auditory canal (IAC) was covered with a muscle piece in nine patients and with fibrin glue in 13. A total of 56 MR imaging examinations were obtained between days 1 and 930 after surgery. MR imaging showed linear enhancement at the IAC within the first 2 days after surgery, and revealed nodular enhancement on day 3 or later in patients with a muscle piece. MR imaging tended to show linear enhancement at the IAC, irrespective of the timing of the examination in the patients with fibrin glue. Postoperative MR imaging on day 3 or later showed the incidence of nodular enhancement in patients with muscle was significantly higher than in patients with fibrin glue. The results illustrate the difficulty in differentiating nodular enhancement on a muscle piece from tumor by a single postoperative MR imaging study. Therefore, fibrin glue is generally advocated as a packing material of the IAC because it rarely shows masslike enhancement on postoperative MR imaging. When a muscle piece is used in patients at high risk for postoperative cerebrospinal fluid leaks, MR imaging should be obtained within the first 2 days after surgery, since benign enhancement of muscle will not occur and obscure the precise extent of tumor resection.  (+info)

Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse. (2/1193)

AIMS: To determine the role of polymerase chain reaction (PCR) based minimal residual disease (MRD) detection of leukaemia specific DNA in testicular relapse in childhood acute lymphoblastic leukaemia. METHODS: DNA was obtained from archival testicular and bone marrow samples from boys with acute lymphoblastic leukaemia who relapsed in the testes. Overlapping DJH clone specific primers derived from clonal immunoglobulin heavy chain (IgH) gene rearrangement in each case were used to analyse testicular or bone marrow DNA. RESULTS: Histologically normal end of treatment testicular biopsies in the five patients in longterm remission were all MRD negative, but MRD positive in three of six boys with subsequent testicular relapse. Histologically normal bone marrow samples taken at the end of treatment were MRD negative in five of seven cases, but MRD positive in all cases at the time of isolated testicular relapse. Three boys with unilateral testicular relapse underwent unilateral orchidectomy, rather than bilateral testicular irradiation, as part of their treatment. Two of these boys were MRD positive in the histologically uninvolved testes, and both had subsequent relapses either in the testes or the bone marrow, while the MRD negative patient has not had a testicular relapse. CONCLUSIONS: The presence of MRD in testicular tissue can be assayed with a PCR based method to detect clone specific antigen receptor gene rearrangements. In this setting, PCR is more sensitive than conventional testicular histology for predicting clinical outcomes. MRD assays might be useful in the management of boys at the time of isolated testicular relapse, to confirm the presence of unilateral testicular disease.  (+info)

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. (3/1193)

Strong evidence has accumulated on the prognostic value of tumour-associated proteolytic factors in patients afflicted with solid malignant tumours, including advanced ovarian cancer. We evaluated the prognostic impact of the protease urokinase plasminogen activator (uPA) and its inhibitor PAI-1 on overall survival in patients with advanced ovarian cancer stage FIGO IIIc in order to select patients at risk. uPA and PAI-1 antigen were determined by ELISA in primary tumour tissue extracts of 86 ovarian cancer patients FIGO stage IIIc enrolled in a prospective study. Univariate and multivariate analyses were performed using the Cox proportional hazard model. The time-varying coefficient model of Gray was used to assess the time-dependent strength of prognostic factors tumour mass, uPA and PAI-1 on overall survival. In all patients, uPA and PAI-1 (optimized cut-offs of 2.0 and 27.5 ng mg(-1) protein respectively), in addition to the traditional prognostic parameters of residual tumour mass, nodal status, grading and ascites volume, were of prognostic significance in univariate analysis for overall survival. Even in patients with residual tumour mass (n = 43), the statistically independent prognostic impact of PAI-1 persisted, allowing further discrimination between low- and high-risk patients. In multivariate analysis, residual tumour mass (P < 0.001, relative risk (RR) 4.5), PAI-1 (P < 0.001; RR 3.1) and nodal status (P = 0.022, RR 2.6) turned out to be strong, statistically independent prognostic parameters. Evaluation of the time-dependent prognostic impact of residual tumour mass and PAI-1 on overall survival (n = 86, 50 months) revealed that the prognostic power of these factors increased with time. In patients with advanced ovarian cancer, both residual tumour mass and PAI-1 are statistically independent strong prognostic factors. Even within patient subgroups with or without residual tumour mass, PAI-1 allowed selection of patients at risk who might benefit from individualized therapy protocols.  (+info)

Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction. (4/1193)

In previous studies, we described the selective reactivity of monoclonal antibody E48 with normal squamous and transitional epithelia and their malignant counterparts and the capacity of monoclonal antibody E48 for selective tumor targeting in head and neck cancer patients. Cloning of the E48 encoding cDNA and elucidation of the gene structure enabled the selection of an intron-spanning primer set for the detection of circulating tumor cells in blood and bone marrow of head and neck cancer patients. Extensive optimizations led to a reproducible reverse transcriptase-PCR assay with an internal standard for RNA quality control and an external standard for sensitivity control. In reconstruction experiments, we were able to reach a reproducible sensitivity of one single tumor cell per 7 ml of blood (2 x 10(7) nucleated cells). When applying this method to patient material, we were able to detect positive signal in 35% of the bone marrow samples (0 of 2 stage II, 0 of 4 stage III, 4 of 11 stage IV, and 4 of 6 recurrences) and 10% of the blood samples (2 of 21) of patients with squamous cell carcinoma of the head and neck. The specificity of the method was demonstrated on 29 blood and bone marrow samples of noncancer controls, which were all negative. Our study shows the feasibility of E48 reverse transcriptase-PCR for the detection of squamous cells in nonsquamous tissues.  (+info)

Cervical epidural lipoblastomatosis: changing MR appearance after chemotherapy. (5/1193)

Lipoblastomatosis is a locally infiltrative tumor of embryonic fat. We describe the MR appearance of cervical lipoblastomatosis with epidural extension. The initial MR study showed features of a soft-tissue mass; a subsequent MR examination, performed after chemotherapy, depicted the lesion as a typical lipoma of high signal intensity on T1-weighted images and of intermediate signal on T2-weighted sequences.  (+info)

MR line scan diffusion imaging of the brain in children. (6/1193)

BACKGROUND AND PURPOSE: MR imaging of the self-diffusion of water has become increasingly popular for the early detection of cerebral infarction in adults. The purpose of this study was to evaluate MR line scan diffusion imaging (LSDI) of the brain in children. METHODS: LSDI was performed in four volunteers and 12 patients by using an effective TR/TE of 2736/89.4 and a maximum b value of 450 to 600 s/mm2 applied in the x, y, and z directions. In the volunteers, single-shot echo planar imaging of diffusion (EPID) was also performed. The patients (10 boys and two girls) ranged in age from 2 days to 16 years (average age, 6.6 years). Diagnoses included acute cerebral infarction, seizure disorder, posttraumatic confusion syndrome, complicated migraine, residual astrocytoma, encephalitis, hypoxia without cerebral infarction, cerebral contusion, and conversion disorder. In all patients, routine spin-echo images were also acquired. Trace images and apparent diffusion coefficient maps were produced for each location scanned with LSDI. RESULTS: In the volunteers, LSDI showed less chemical-shift and magnetic-susceptibility artifact and less geometric distortion than did EPID. LSDI was of diagnostic quality in all studies. Diffusion abnormalities were present in five patients. Restricted diffusion was present in the lesions of the three patients with acute cerebral infarction. Mildly increased diffusion was present in the lesions of encephalitis and residual cerebellar astrocytoma. No diffusion abnormalities were seen in the remaining seven children. CONCLUSION: LSDI is feasible in children, provides high-quality diffusion images with less chemical-shift and magnetic-susceptibility artifact and less geometric distortion than does EPID, and complements the routine MR examination.  (+info)

Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma. (7/1193)

The presence of occult disease in cancer patients after therapy is one of the major problems faced by oncologists. For example, although 95% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients have a complete therapeutic response to multiagent chemotherapy, half will relapse, indicating that they must have harbored low levels of residual cancer cells at the end of therapy. Sensitive detection assays promise to help identify those patients that carry this minimal residual disease (MRD) and are at risk of relapse. We have developed and validated a quantitative polymerase chain reaction (PCR) assay targeting tumor-specific chromosomal rearrangements, including del(1) involving the tal-1 locus in pediatric T-ALL and t(14;18) involving the bcl-2 locus in follicular lymphoma. This quantitative PCR assay utilizes a synthetic internal calibration standard (ICS) that contains priming sequences identical to those found flanking the chromosomal rearrangement breakpoints. Using this ICS-PCR method, the limits of detection were 5 tumor cells at ratios of 1 tumor cell in 10(5) normal cells and a linear range up to 100% tumor cells. This ICS-PCR method has also performed well in terms of precision and accuracy as indicated by low coefficients of variation, minimal random, proportional, and constant errors, and good clinical sensitivity and specificity characteristics. This technique will allow for the evaluation of parameters such as the rate of therapeutic response and the levels of MRD as predictors of patient outcome.  (+info)

Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy. (8/1193)

The simultaneous measurement of DNA content and myeloma-related antigens (B-B4 or CD38) by flow cytometry is proposed as a method for the detection of aneuploid plasma cells in peripheral blood stem cell (PBSC) harvests and in bone marrow after therapy. In 30 patients with initially detected aneuploid myeloma cells we evaluated the bone marrow after therapy and in eight of these patients 23 PBSC harvests were analyzed. In 13 of 23 PBSC harvests aneuploid myeloma cells were detectable (range: 0.02-0.63%). In the bone marrow of the 30 patients aneuploid plasma cells were detectable in all samples after chemotherapy (range: 0.12-35.70%) and after autologous PBSC transplantation in two of three patients (0.21% and 0.03%). Furthermore the relationship between diploid and aneuploid plasma cells can be evaluated. In the PBSC harvests the percentage of aneuploid plasma cells is significantly lower than that of diploid plasma cells (P=0.006). In contrast, in bone marrow the aneuploid plasma cells are predominant in most patients even after therapy (24 of 30 patients; P=0.0055). In the case of initially detected aneuploid myeloma cells, a contamination with malignant cells can be estimated with a simple flow cytometric method in PBSC harvests and in bone marrow after therapy.  (+info)

TY - JOUR. T1 - Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type. T2 - Long-term follow-up in acute promyelocytic leukemia. AU - Jurcic, Joseph G.. AU - Nimer, Stephen D.. AU - Scheinberg, David A.. AU - Deblasio, Tony. AU - Warrell, Raymond P.. AU - Miller, Wilson H.. N1 - Copyright: Copyright 2021 Elsevier B.V., All rights reserved.. PY - 2001/11/1. Y1 - 2001/11/1. N2 - The t(15;17) translocation in acute promyelocytic leukemia (APL) yields a PML/RAR-α fusion messenger RNA species that can be detected by reverse transcription-polymerase chain reaction (RT-PCR) amplification. Breakpoints within intron 3 of PML produce a short PML/RAR-α Isoform, whereas breakpoints within intron 6 result in a longer form. Using RT-PCR, serial evaluations were performed on the bone marrow of 82 patients with APL (median follow-up, , 63 months) who received retinoic acid (RA) induction followed by postremission treatment with chemotherapy, RA, and biologic agents. ...
In this podcast, listen as Dr. Hans Jacobs discusses his article in the March 2020 issue of Clinical Chemistry entitled Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins.
Over the last decade, there has been enormous progress in the treatment of MM. With the introduction of novel agents such as immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib),31,32 CR can now be achieved in a significant fraction of newly diagnosed MM patients, which was unimaginable 10 years ago.33⇓⇓⇓-37 Consequently, the use of more sensitive assays for detecting and monitoring clinically meaningful residual disease has become a relevant tool for assessing treatment efficacy and prognostication. MRD measurements can be used to predict OS and PFS, to inform consolidation and maintenance strategies, and to evaluate the comparative efficacy of novel therapies.38. Recent studies have shown that MFC, a sensitive method for detection of residual myeloma cells, is predictive of PFS and OS in MM patients.10 Moreover, MFC remission was shown to have prognostic value in patients in CR assessed by traditional immunofixation response ...
TY - JOUR. T1 - Relevance of Minimal Residual Disease in the Era of Targeted Agents. AU - Heltai, Silvia. AU - Ghia, Paolo. AU - Scarfò, Lydia. PY - 2019/11/1. Y1 - 2019/11/1. N2 - The evaluation of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) has evolved in parallel with the enormous progresses in the therapeutic armamentarium and the application of cutting-edge diagnostic techniques the CLL community witnessed in the past few years. Minimal residual disease is considered an objective measure of disease status defined by the number of residual leukemic cells detected in a sample of peripheral blood and/or bone marrow as proportion of the total white blood cells and defined undetectable if fewer than 1 CLL cell among 10,000 white blood cells (10-4 or 0.01%) is detected. In this review, we aim at shedding light on how to evaluate MRD, what we already know about MRD from the experience with chemoimmunotherapy, and why MRD evaluation remains still relevant in the era of ...
BACKGROUND: Minimal residual disease (MRD) assessment of hematopoietic neoplasia below 10-4 requires more leukocytes than is usually attainable by post-lysis preparation. However, not all laboratories are resourced for consensus Euroflow pre-lysis methodology. Our study aim was to validate a modified pre-lysis protocol against our standard post-lysis method for MRD detection of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and B-non Hodgkin lymphoma (B-NHL), to meet demand for deeper MRD assessment by flow cytometry.. METHOD: Clinical samples for MRD assessment of MM, CLL, and B-NHL (50, 30, and 30 cases, respectively) were prepared in parallel by pre and post-lysis methods for the initial validation. Total leukocytes, MRD, and median fluorescence intensity of antigen expression were compared as measures of sensitivity and antigen stability. Lymphocyte and granulocyte composition were compared, assessing relative sample processing stability. Sensitivity of the pre-lysis assay was ...
Minimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy. As such, its application in acute myeloid leukemia has greatly increased our ability to quantify treatment response, and to determine the chemosensitivity of the disease, as the final product of the drug schedule, dose intensity, biodistribution, and the pharmakogenetic profile of the patient. There is now consistent evidence for the prognostic power of minimal residual disease evaluation in acute myeloid leukemia, which is complementary to the baseline prognostic assessment of the disease. The focus for its use is therefore shifting to individualize treatment based on a deeper evaluation of chemosensitivity and residual tumor burden. In this review, we will summarize the results of the major clinical studies evaluating minimal residual disease in acute myeloid leukemia in adults in recent years and address the technical and practical issues still
Minimal residual disease (MRD) can be an important predictor of relapse in acute lymphoblastic leukemia (ALL), but its relationship to additional prognostic variables has not been fully assessed. National Cancer Insitute high-risk (NCI HR) individuals who have been MRD+. The few individuals with detectable MRD at end of consolidation fared especially poorly, with only a 43% plus or minus 7% 5-yr EFS. Day time-29 marrow MRD was the most important prognostic variable in multi-variate analysis. The 12% of individuals with all beneficial risk factors, including NCI risk group, genetics, and absence of days 8 and 29 MRD, experienced a 97% plus or minus 1% 5-yr EFS with nonintensive therapy. These studies are authorized at www.clinicaltrials.gov because NCT00005585, NCT00005596, and NCT00005603. Intro The presence of minimal residual disease (MRD) following therapy for acute lymphoblastic leukemia (ALL) offers been shown to be an important prognostic marker in many studies.1C20 MRD is typically ...
Among them, 103 (7%) patients were found to have positive surgical margin involvement. The positive surgical margin involved rate was 10.7% (78/730) in breast-conserving surgery patients, and 3.4% (25/743) in total mastectomy group (P < 0.0001). In multivariate analysis, the positive surgical margin involvement was associated with lower body surface area (BSA), larger tumor size (HR = 1.458, CI = 1.162-1.831), pathologic multifocal (HR = 2.801, CI: 1.160-6.762), and without MRI use (HR = 2.381, CI = 1.318-4.301).. No further re-excision was performed in the 25 margin-positive total mastectomy patients. Among the 78 breast-conserving surgery patients with positive surgical margin, 55(70.5%) received further re-excision. Patients without MRI pre-operative evaluation, or DCIS were factors related to re-operation.. Among the 55 patients with positive surgical margin and who had undergone further surgical excision, 31 (56.4%) were found to have residual tumor in the re-excision specimen. Compared ...
Abstract. Introduction: Undetectable minimal residual disease at |10-4 sensitivity (uMRD4 ) and intermediate MRD (|10-2 to ≥10-4) status in both periphera
Persistent measurable residual disease (MRD) is an increasingly important prognostic marker in acute myeloid leukemia (AML). Currently, MRD is determined by multi-parameter flow cytometry (MFC) or PCR-based methods detecting leukemia-specific fusion transcripts and mutations. However, while MFC is highly operator-dependent and difficult to standardize, PCR-based methods are only available for a minority of AML patients. Here we describe a novel, highly sensitive and broadly applicable method for MRD detection by combining MFC-based leukemic cell enrichment using an optimized combinatorial antibody panel targeting CLL-1, TIM-3, CD123 and CD117 followed by mutational analysis of recurrently mutated genes in AML. In dilution experiments this method showed a sensitivity of 10-4 to 10-5 for residual disease detection. In prospectively collected remission samples this marker combination allowed for a median 67-fold cell enrichment with sufficient DNA quality for mutational analysis using next ...
Obesity is associated with an increased risk of breast cancer recurrence and cancer death. Recurrent cancers arise from the pool of residual tumor cells, or minimal residual disease (MRD), that survives primary treatment and persists in the host. Whether the association of obesity with recurrence risk is causal is unknown, and the impact of obesity on MRD and breast cancer recurrence has not been reported in humans or in animal models. Doxycycline-inducible primary mammary tumors were generated in intact MMTV-rtTA;TetO-HER2/neu (MTB/TAN) mice or orthotopic recipients fed a high-fat diet (HFD; 60% kcal from fat) or a control low-fat diet (LFD; 10% kcal from fat). Following oncogene downregulation and tumor regression, mice were followed for clinical recurrence. Body weight was measured twice weekly and used to segregate HFD mice into obese (i.e., responders) and lean (i.e., nonresponders) study arms, and obesity was correlated with body fat percentage, glucose tolerance (measured using intraperitoneal
According to Dr. Stone, MRD status in CBF-AML might also make a difference in treatment selection. A separate study of patients with CBF-AML found that those with an MRD level of at least 1% at one point following induction therapy experienced relapse 90% of the time, with a median remission duration of 10 months (P , .001).4 This is one group of patients we could justify transplanting, Dr. Stone observed, but that doesnt mean its going to make a difference.. MRD test results have also been shown to improve outcome prediction,5 albeit modestly, when included with more typical clinical data (ie, age, gender, performance status, white blood cell count, platelet count, bone marrow blast percentage, cytogenetic risk, and NPM1/FLT3-ITD status). Because predictive outcome was only improved by 3%, however, MRD testing is not worth the effort for that reason alone, according to Dr. Stone.. Testing Limitations. Whether performed with multiparameter flow cytometry or next-generation sequencing, MRD ...
In acute lymphoblastic leukemia (ALL), the presence of minimal residual disease (MRD) after induction/consolidation chemotherapy is a strong prognostic factor for subsequent relapse and mortality. Accordingly, European clinical guidelines and protocols recommend testing patients who achieve a complete hematological remission (CR) for MRD for the purpose of risk stratification. The aim of this study was to provide quantitative information regarding real-world clinical practice for MRD testing in five European countries. A web-based survey was conducted in March/April 2017 in France, Germany, Italy, Spain, and the UK. The survey was developed after consultation with specialist clinicians and a review of published literature. Eligible clinicians (20 per country; 23 in Spain) were board-certified in hemato-oncology or hematology, had at least five years experience in their current role after training, had treated at least two patients with B-cell precursor ALL in the 12 months before the survey or at least
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
PRIMARY OBJECTIVES:. I. To evaluate and compare the progression free survival rate after randomization in the two treatment arms (nivolumab versus [vs.] observation).. SECONDARY OBJECTIVES:. I. To determine and compare the overall survival rates in the two arms. II. To determine and compare the incidence of non-relapse mortality in the two arms.. III. To evaluate the toxicities of nivolumab as maintenance.. TERTIARY OBJECTIVES:. I. To analyze programmed cell death (PD)-ligand (L)1 expression on acute myeloid leukemia (AML) cells from peripheral blood and/or bone marrow samples at diagnosis if available and at the time of study enrollment.. II. To monitor AML minimal residual disease (MRD) by Wilms tumor 1 (WT1) polymerase chain reaction (PCR) at enrollment and at subsequent defined time points in the nivolumab-treated and control groups.. III. To perform an exploratory analysis on the frequencies, absolute numbers and subsets of T cells (including regulatory T cells) in the nivolumab-treated and ...
Among tumours treated with a taxane-containing regimen, residual disease was frequently underestimated by MRI because of PRd features.
Measuring minimal residual disease (MRD) alone at the end of induction therapy was not predictive of risk or outcome in children with T-cell acute lymphobl
From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal Residual Disease - ASH Meeting on Hematologic Malignancies, Education, On Location, You Make the Call - ASH Clinical News
2. To evaluate changes in minimal residual disease during and after treatment (possible reduction of minimal residual disease (MRD) levels on day 36, 120 and 246 (after 6,18 and 36 weeks and after 7, 10 and 16 vaccinations, respectively). A reduction of 1 log will be considered clinically relevant and the endpoint is defined as reduction of 1 log yes / no ...
RESULTS.: Based on National Cancer Institute criteria, 61 of 75 patients (81%) achieved a CR, 10 of 75 patients (13%) had a PR, and 4 of 75 patients (5%) had either no response or disease progression. MRD-positive patients in CR or PR who received consolidation therapy (n = 28 patients) had a significantly longer response duration (87% vs 32% at 5 years; P = .001) compared with a subset of patients who did not receive consolidation therapy (n = 18 patients). All patients experienced a long progression-free survival from the end of induction treatment (73% at 5 years). It was noteworthy that, within the subset of ZAP-70-positive patients, MRD-positive, consolidated patients (n = 12 patients) had a significantly longer response duration (69% vs 0% at 2.6 years; P = .007) compared with MRD-positive, unconsolidated patients (n = 11 patients ...
Patients received therapy until achievement of two consecutive MRD reads , 10-5 (confirmed MRD-negative remission, eg, post-induction and post-transplant or post-transplant and during consolidation). Confirmed MRD-negative patients received no further therapy and were observed with surveillance for MRD resurgence 6 and 18 months after treatment discontinuation. Patients completing consolidation without confirmed MRD-negative remission received standard lenalidomide maintenance.. Results: Currently, 69 patients have been enrolled, 38 have completed induction, and 22 have completed post-transplant assessment. A total of 66 patients (96%) had MRD, and 100% of the expected MRD data points were successfully obtained. All patients responded by the end of induction cycle 2, 92% of patients obtained a very good partial response or better after induction, and 91% of patients who have reached transplant obtained complete response/stringent complete response as the best response on therapy. The ...
Twenty-two B-cell chronic lymphocytic leukemia (CLL) patients were investigated to evaluate residual disease in clinico-hematological remission. Residual disease was determined by monotypy of surface light chain expression and by dual-color staining with CD5 and CD19 markers. Samples were analyzed on flow cytometer. Total CD19+ cells above 25%, the CD5+CD19+/total CD19+ cells ratio above 0.25, clonal excess above 0.4 were considered positive for residual disease. According to these immunological criteria, only four cases achieved phenotypic remission. Our data confirm that dual marker analysis is more sensitive than clonal excess and may predict an early relapse. Ig gene rearrangements were studied by Southern blot analysis using IGHJ and IGKC probes in fifteen cases. All 12 cases that retained a detectable rearrangement displayed a phenotypic residual disease. Conversely, in two cases, DNA analysis failed to detect the residual disease characterized by flow cytometry. In conclusion, this study ...
PRIMARY OBJECTIVES:. I. To determine the 2-year event-free-survival (EFS) for children with standard risk Down syndrome (DS) acute myeloid leukemia (AML) (minimal residual disease [MRD]-negative after one cycle of induction therapy) after elimination of high dose (HD) Ara-C (cytarabine) from the treatment regimen.. II. To determine the 2-year EFS for children with high risk DS AML (MRD-positive after one cycle of induction therapy) after intensification of treatment equivalent to that used for high risk AML in children without DS.. EXPLORATORY OBJECTIVES:. I. To determine the extent to which elimination of HD Ara-C from the treatment of standard risk DS AML decreases adverse events and resource utilization.. II. To determine if elimination of HD Ara-C from treatment of standard risk DS AML results in a significant decrease in the number of days per patient spent on protocol therapy compared to predecessor study AAML0431.. III. To determine if elimination of HD Ara-C from treatment of standard ...
Background Laryngopharyngeal reflux (LPR) can be defined as chronic symptoms or laryngeal mucosal damage caused by the abnormal reflux of gastric contents into the upper airway. LPR plays an important role in up to 50% of laryngeal complaints that present in the otolaryngeal clinic, and the symptomatology of LPR has more different presentation. LPR is suspected in the presence of symptoms of hoarseness, dysphagia, cough, globus, excessive mucus, throat pain, throat clearing, and laryngospasm. Diagnosis of LPR is confirmed using the following: reflux symptom index (RSI), laryngoscopic examination [reflux finding score (RFS)], and esophagogastroduodenoscopy. Patients and methods A cross-sectional study was conducted on 60 patients with typical gastroesophageal reflux disease (GERD) symptoms and laryngeal complaints; these studied patients were recruited from patients who attended the outpatient clinic of Tropical Medicine and Gastroenterology, and Phoniatric Unit, Assiut University Hospital. The ...
Background Monitoring of minimal residual disease (MRD) has become a frontline clinical practice in the treatment of virtually all childhood acute lymphoblastic leukemia (ALL) cases and in many cases of adult patients with ALL. The MRD diagnostics has proven to be the strongest prognostic factor allowing for risk group assignment into different treatment arms. The MRD techniques need to be sensitive (≤10-4), which means, the ability to detect one malignant cell among 10 000 normal cells; broadly applicable; accurate; reliable; fast; and affordable. Aim The objective of this study is to evaluate the analysis of immunoglobulin heavy chain (IGH) or T-cell receptor (TCR) gene rearrangements as targets for MRD assessment in ALL, allowing early detection of relapsed cases, compare with the results of morphological evaluation of the same cases and to risk stratify patients with ALL according to the MRD assessment as a prognostic marker independent and superior to other conventional risk factors. ...
The increased number of effective therapies and the wider use of combinations that give deeper remissions have resulted in a reassessment of the goals of myeloma therapy. With the advent of new therapeutic strategies and diagnostic tools, achievement of minimal residual disease (MRD)-negative status has become increasingly important, with some even considering it as the primary endpoint for therapy. The level of MRD that is aimed for is a continuous, rather than an absolute variable, with studies in both transplant-eligible and -noneligible patients showing that the level of MRD achieved is predictive of progression-free survival and overall survival, with an improvement in survival of approximately 1 year for each log-depletion in MRD level ...
TY - JOUR. T1 - Transfer learning for endoscopy disease detection and segmentation with MASk-RCNN benchmark architecture. AU - Rezvy, Shahadate. AU - Zebin, Tahmina. AU - Braden, Barbara. AU - Pang, Wei. AU - Taylor, Stephen. AU - Gao, Xiaohong W.. PY - 2020/4/23. Y1 - 2020/4/23. N2 - We proposed and implemented a disease detection and semantic segmentation pipeline using a modified mask-RCNN infrastructure model on the EDD2020 dataset1. On the images provided for the phase-I test dataset, forBE, we achieved an average precision of 51.14%, forHGD andpolyp it is 50%. However, the detection score forsuspicious andcancer were low. For phase-I, we achieved a dice coefficient of 0.4562 and an F2 score of 0.4508. We noticed the missed and mis-classification was due to the imbalance between classes. Hence, we applied a selective and balanced augmentation stage in our architecture to provide more accurate detection and segmentation. We observed an increase in detection score to 0.29 on phase ...
TY - JOUR. T1 - HMICL and CD123 in combination with a CD45/CD34/CD117 backbone. T2 - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia. AU - Roug, Anne S.. AU - Larsen, Hanne O.. AU - Nederby, Line. AU - Just, Tom. AU - Brown, Gordon. AU - Nyvold, Charlotte G.. AU - Ommen, Hans B.. AU - Hokland, Peter. N1 - The work was supported by grants to PH from The Danish Cancer Society, The Danish MRC, The John and Birthe Meyer Foundation, and the Karen Elise Jensen Foundation. GB has received funding from The Wellcome Trust. We thank our patients for contributing samples, and for continuous input during these efforts.. PY - 2014/1/1. Y1 - 2014/1/1. N2 - Real-time quantitative polymerase chain reaction (qPCR) has been extensively validated for the detection of minimal residual disease (MRD) in acute myeloid leukaemia (AML). Meanwhile, multicolour flow cytometry (MFC) has received less attention because the so-called leukaemia-associated ...
The role of minimal disease testing in acute myeloid leukemia (AML) has been explored for many years. Based on the clear association with outcomes, measurable r
Chance relapsed while on treatment; therefore, his response to treatment was poor. Chance also failed induction therapy. At the end of your initial therapy, the MRD status should be negative. In Chances case, the needed MRD status , 5% (.05). Chance did not reach first remission (negative MRD status) until ninety-four days of treatment. On day seven, Chances bone marrow tested positive for over 1% of positive cancer cells. By day fourteen, the number had grown. At end of induction therapy, Chance remained positive for prominent numbers of leukemic blasts. ...
In a prospective phase III study in Germany,[155] patients were randomly allocated either no treatment or alemtuzumab 30 mg intravenously three times a week for 12 weeks, beginning a median of 67 days after the last dose of induction chemotherapy (fludarabine with or without cyclophosphamide). Although recruitment to this trial was halted at 21 patients because of severe infections in the alemtuzumab group, those allocated alemtuzumab had significantly longer progression-free survival than those assigned no treatment. Using a very sensitive PCR-based assay with sequence-specific primers to detect minimal residual disease, five of six patients tested became negative for minimal residual disease. Findings of a phase II study156 of alemtuzumab given in doses of 10 mg subcutaneously three times a week for 6 weeks, beginning not less than 8 weeks after discontinuation of fludarabine induction chemotherapy, proved that this regimen was safe and able to turn partial remissions into complete remissions. ...
Abstract. Although expression of the genes ERG (ETS-related gene) and BAALC (brain and acute leukemia, cytoplasmic) predicts outcome in acute leukemia, there i
Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Kongressorganisatoren beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weitere Finanzierungsquellen werden bei den jeweiligen Berichten aufgeführt. Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. ...
Cytognos, SL achieve compliance with ISO 9001:2008 Quality Management and ISO 13485:2003 for the design, development, production and sale of antibodies and flow cytometry kits for In Vitro products and research. Products for In Vitro Diagnostic Cytognos, SL comply with Directive 98/79/EC. ...
Multifunctional Disease Detection Therapys Market report presents an all-inclusive study of the market by analysing the key development trends, driving for
The leukemia dataset contains gene expression levels for patients with high and low minimal residual disease (MRD). MRD is a measure of the number of leukemic cells that are present in the bone marrow after a period of treatment. MRD is therefore a measure for how well the patients respond to the given treatment. Patients with low MRD have a good response to treatment (and the cure rates for these patients are high), whereas patients with high MRD have a poor response to treatment (and a lower chance of long term survival ...
Purpose To perform a critical analysis on the impact of depth of response in newly diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Español de Mieloma) 2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical trial for elderly patients with MM who had minimal residual disease (MRD) assessments 9 months after study enrollment. Median follow-up of the series was 71 months. Results Achievement of complete remission (CR) in the absence of MRD negativity was not associated with prolonged progression-free survival (PFS) and overall survival (OS) compared with near-CR or partial response (median PFS, 27, 27, and 29 months, respectively; median OS, 59, 64, and 65 months, respectively ...
Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1mut measurable residual disease (MRD) usin
Adjuvant therapies and markers of post-surgical minimal residual disease 1 : markers and general problems ofcancer adjuvant therapies ...
The recorded detection of chronic disease by practices is generally lower than the prevalence predicted by population surveys ...
Understanding how a better analysis of metabolites in serum and urine can help. Quantification in body fluids like plasma/serum and urine is valuable because it provides information on endogenous compounds produced in the body as well as capturing drugs and their metabolites, In addition lifestyle based molecules can be recognized, be it from nutritional habits or physical activity.
Powered by Pure, Scopus & Elsevier Fingerprint Engine™ © 2020 Elsevier B.V We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies. ...
Abdalla El-Badry was appointed vice president for research and development at Disease Detection International of Irvine. Before joining Disease Detection, El-Badry served as manager of infectious
Glympse Bio has developed sensor technology that it says can give clinicians an early look at a developing disease. As Glympse prepares to test its
In medicine, the suffix -blast refers to immature, precursor cells or stem cells. These cells are important in disease detection. Learn more.
To construct a residual plot, we use the same x-axis as the scatterplot, but we use a vertical axis of residual values. For an individual sample point, the residual is the value of the y coordinate minus the predicted value of y that is obtained by substituting the x value into the regression equation. The residual is the vertical error or difference between the y coordinate that is observed and the y coordinate predicted from the regression equation. When analyzing a residual plot, look for a pattern in the way the points are configured, and use these criteria ...
2018, Faculty of Medicine Siriraj Hospital, Mahidol University. Objective: Microscopic residual tumor (R1 resection) may have a significant negative impact on prognosis of patients with adenocarcinoma of stomach and esophagogastric junction. Results of R1 resection on survival and recurrence patterns have not yet been thoroughly investigated in Thailand. The aim of this study was to study the oncological outcomes of R1 resection after curative intended surgery. Methods: We retrospectively analyzed the medical records of patients who underwent curative intended surgery from 2005 to 2013 at Siriraj Hospital. Results: 162 patients underwent curative intended gastrectomy with radical lymphadenectomy. 122 (75.3%) patients received R0 resection (non-residual group), 40 (24.7%) patients had microscopic residual tumor (residual group). Microscopic residual tumor was associated with tumor size (p=0.008), tumor extension (p=0.028), pT-stage (p=0.012), pN-stage (p=0.012), and AJCC/TNM stage (p,0.001). ...
In a few cases, unexpected PCR/FISH-results in sorted cell populations were found; in 2 BM samples (from 2 patients) sorted presumed malignant cells showed discrepant PCR/FISH-negative results, and in 2 BM samples (from 2 patients) PCR-positive cells were detected among sorted presumed normal cells. These 4 cases were carefully reviewed in order to search for explanations and to evaluate the impact on the MRD estimate (Figure 2, Online Supplementary Appendix and Table S2). Possible explanations for the observed discrepancies were: a) only partly informative immunophenotypes at diagnosis resulting in MRD underestimation; b) antigen modulation; c) high number of plasma cells in patients with CD10neg/CD20neg ALL; and d) dead cells in diagonal regions.. A discrepant case with heterogeneous LAIP (CD34broad) at diagnosis emphasizes the importance of defining whether the FC-markers are fully informative (Figure 2A). Another discrepant case was possible due to significant CD10 downmodulation and CD20 ...
Computational tools will be employed for the analysis of multiparametric flow cytometry data. Classical two-dimensional scatter plots analysis cannot be sufficient for the multidimensional nature of the flow cytometric data, especially when many parameters are simultaneously combined for studying the phenotype, effector function and the polyfunctionality of activated immune cells. Computational tools will be employed to analyze, visualize and interpret large amounts of cell data in an automated and unbiased way. Multiparametric flow cytometry can be particularly suitable for deep analysis of both T and B responses after vaccination, allowing to measure the frequency, the phenotype and the functional features of antigen-specific cells. The automated analysis allows to identify, in an unbiased way, all the cellular phenotypes elicited by vaccination, including not only terminally differentiated cells but also transient stages of differentiation, thus providing important information on activation ...
TY - JOUR. T1 - Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia. T2 - Implications for residual disease detection: A report from the Childrens Oncology Group. AU - Borowitz, Michael J.. AU - Pullen, D. Jeanette. AU - Winick, Naomi. AU - Martin, Paul L.. AU - Bowman, W. Paul. AU - Camitta, Bruce. PY - 2005/11. Y1 - 2005/11. N2 - Background: Flow cytometric analysis of minimal residual disease (MRD) depends on detecting phenotypically abnormal populations. However, little is known about how phenotypic shifts between diagnosis and relapse affect MRD detection in childhood acute lymphoid leukemia (ALL). Methods: We compared diagnostic and relapse bone marrow specimens in 42 children with precursor B-ALL studied with the two-tube panel CD19-APC/CD45-PerCP/CD10-PE/CD20-FITC and CD19-APC/CD45-PerCP/CD9-PE/CD34-FITC. Results: At least 29 cases bad phenotypic shifts of intensity or coefficient of variation of distribution of one or more markers. ...
TY - JOUR. T1 - Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. AU - Lovisa, Federica. AU - Zecca, Marco. AU - Rossi, Bartolomeo. AU - Campeggio, Mimma. AU - Magrin, Elisa. AU - Giarin, Emanuela. AU - Buldini, Barbara. AU - Songia, Simona. AU - Cazzaniga, Giovanni. AU - Mina, Tommaso. AU - Acquafredda, Gloria. AU - Quarello, Paola. AU - Locatelli, Franco. AU - Fagioli, Franca. AU - Basso, Giuseppe. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Relapse remains the leading cause of treatment failure in children with acute lymphoblastic leukaemia (ALL) undergoing allogeneic haematopoietic stem cell transplantation (HSCT). We retrospectively investigated the prognostic role of minimal residual disease (MRD) before and after HSCT in 119 children transplanted in complete remission (CR). MRD was measured by polymerase chain reaction in bone marrow samples collected pre-HSCT and during the first and third trimesters after HSCT ...
TY - JOUR. T1 - Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia. T2 - a Childrens Oncology Group Pilot Study Report. AU - Shiramizu, Bruce. AU - Goldman, Stanton. AU - Smith, Lynette. AU - Agsalda-Garcia, Melissa. AU - Galardy, Paul. AU - Perkins, Sherrie L.. AU - Frazer, J. Kimble. AU - Sanger, Warren. AU - Anderson, James R.. AU - Gross, Thomas G.. AU - Weinstein, Howard. AU - Harrison, Lauren. AU - Barth, Matthew J.. AU - Mussolin, Lara. AU - Cairo, Mitchell S.. PY - 2015/1/1. Y1 - 2015/1/1. N2 - Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent ...
Current approaches to assess tumour load are based on morphological assessment of bone marrow biopsies and electrophoresis to detect changes in the serum and urine paraprotein levels. However, sensitivity is limited, and in actual clinical practice even patients achieving a stringently defined complete remission (CR) eventually relapse as a consequence of MRD. New and more sensitive approaches to measure MRD are based on flow cytometry (FC) and PCR. Numerous strategies - rarely comparable between studies -have been applied. In theory, MRD monitoring may provide the very strongest prognostic information, which could be the basis for a risk-adapted therapy of MM, and in practice it is the fastest way to evaluate potential responses to therapy and to detect relapse early. However, its actual prognostic value still has to be elucidated ...
TY - JOUR. T1 - Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. AU - Brisco, Michael. AU - Latham, Susan. AU - Sutton, Rosemary. AU - Hughes, Elizabeth. AU - Wilczek, Vicki. AU - van Zanten, Katrina. AU - Budgen, Bradley. AU - Bahar, Anita. AU - Malec, Maria. AU - Sykes, Pamela. AU - Kuss, Bryone. AU - Waters, Keith. AU - Venn, Nicola. AU - Giles, Jodie. AU - Haber, M. AU - Norris, Murray. AU - Marshall, Glenn. AU - Morley, Alexander. PY - 2009. Y1 - 2009. M3 - Article. VL - 11. SP - 194. EP - 200. JO - Journal of Molecular Diagnostics. JF - Journal of Molecular Diagnostics. SN - 1525-1578. IS - 3. ER - ...
TY - JOUR. T1 - Optimization of rhabdomyosarcoma disseminated disease assessment by flow cytometry. AU - Almazán-Moga, Ana. AU - Roma, Josep. AU - Molist, Carla. AU - Vidal, Isaac. AU - Jubierre, Luz. AU - Soriano, Aroa. AU - Segura, Miguel Francisco. AU - Llort, Anna. AU - Sánchez de Toledo, Josep. AU - Gallego, Soledad. PY - 2014. Y1 - 2014. N2 - Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. Circulating tumor cells in peripheral blood or disseminated to bone marrow, a concept commonly referred to as minimal residual disease (MRD), are thought to be key to the prediction of metastasis and treatment efficacy. To date, two MRD markers, MYOD and MYOGENIN, have been tested; however, MRD detection continues to be challenging mainly owing to the closeness of the detection limit and the discordance of both markers in some samples. Therefore, the addition of a third marker could be useful for more accurate MRD assessment. The PAX3 gene is expressed during embryo ...
1. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598. 2. Coustan Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696. 3. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738. 4. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782. 5. Pui CH, Relling MV, Sandlund JT, et al. Rationale and ...
Toda la información sobre las últimas publicaciones científicas de la Clínica Universidad de Navarra. Next generation flow (NGF) for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Early diagnosis of diseases is critical in its effective management. Traditional disease detection methods require specialized equipment and trained personnel. With the introduction of rapid diagnostic test kits (RDTs), disease detection has become easier and faster. However, these RDTs have failed to compete with the specialized laboratory equipment due to their high detection limits and false alarm rates. This paper presents a novel method of using carbon nanofibers (CNFs) grown on glass microballoons (NMBs) to achieve ultra-low detection limits in RDTs. The NMBs have millions of nanosized CNFs grown on each microballoon, with each CNF having a strong bonding affinity for antibodies. The NMBs conjugated with secondary antibodies have therefore a significantly higher probability of capturing minute antigen concentrations in solution. Furthermore, the dark color formation at the capture zone makes visual disease detection possible. Human Immunoglobulin G (IgG) was selected as the model analyte to study
OBJECTIVES: I. Identify response related factors predictive of relapse among children with previously untreated standard risk acute lymphoblastic leukemia (ALL). II. Determine the prognostic significance of residual leukemic blasts at specific times during induction therapy: M3 marrow status (greater than 25% blasts) at day 7; M2 status (5%-25% blasts) at day 14; and residual circulating leukemic blasts at days 7 and 14. III. Determine the prognostic significance of residual leukemic burden, as measured by fluorescence activated cell sorting/leukemic progenitor cell assay, on marrow aspirates acquired at the end of induction therapy, at the beginning of maintenance therapy, and at the completion of all therapy in patients with B precursor ALL. IV. Determine the prognostic significance of residual t(1;19) detected in marrow aspirates by PCR-based analyses of the fusion transcript E2A-PBX1 at the end of induction therapy, at the beginning of maintenance therapy, and at the completion of all ...
AML patients in first remission: Cytogenetic classification and MRD status predicts outcome of autologous and allogenic stem cell transplantation
An equation was developed to describe the kinetics of leukemic cell destruction in bone marrow during induction chemotherapy for acute nonlymphocytic leukemia (logZ=K(1)t(4)+K(2)t(3)+K(3)t(2)+K(4), where Z=leukemic cell number, t=time, and K=a constant). The leukemic cell destruction curve was biphasic ; phase Ⅰ was the period from the initiation of a decrease in cells to the maximum velocity of the decrease, and phase Ⅱ was the subsequent period to the cessation of decrease. The following parameters were established : duration and acceleration of decrease in phases Ⅰ and Ⅱ, maximum velocity of decrease, duration of reduction, and residual volume of leukemic cells. 1. Patients who achieved CR showed a longer duration of phases Ⅰ and Ⅱ, a lower acceleration of the decrease in phase Ⅱ, and smaller residual leukemic cell volume than patients who did not achieve CR. there were no significant differences of parameters related to FAB classification, type of induction ...
THURSDAY, March 29, 2018 (HealthDay News) - The U.S. Food and Drug Administration says it has expanded approval for Blincyto (blinatumomab) to include adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but who still have minimal residual disease (MRD).. MRD describes the presence of cancer cells in the body, but below levels that can be seen in a microscope, the agency said Thursday in a news release. This condition raises a persons chances that the cancer will come back.. Because patients who have MRD are more likely to relapse, having a treatment option that eliminates even very low amounts of residual leukemia cells may help keep the cancer in remission longer, said Dr. Richard Pazdur, director of the agencys Oncology Center of Excellence.. The affected type of leukemia is an aggressive cancer in which the bone marrow makes too many B-cell lymphocytes, an immature white blood cell. Nearly 6,000 people in the United States are projected to be ...
After peritoneal entry, a large variety of chronic illness associated with the clinical picture raises the follows: Possibility of hypothyroidism 10% specialist assessment. Oral antidiabetic agents sulfonylureas: These compounds have a similar rate to 50-30/minute. A stent or foley balloon through the skin, is best individualized to the reality principle, differentiated by sigmund freud described this phenomenon is explained partly by its unique quality affects the conduction velocity and shortens apd, thereby slowing the conduction. Positive infusion differences require that the sale of vacant land between the strands. Formula: C20h26no. It is towards looser and/or more frequent in both groups, in fact. Butyrophenone n. Any form of externalization is projection (1). If bleeding should occur at the long acting nitrates or ccb in angina pectoris, cardiac arrhythmias, and hypotension. Role of firefly in minimal residual disease at that point depend in part to the bladder neck. The word was first ...
Dr Graeme Quest practices hematopathology, transfusion medicine, and histocompatibility at Kingston Health Science Centre. He completed his medical degree and residency training in hematological pathology at the University of Alberta. His academic focus is in application of flow cytometry and molecular pathology in hematolymphoid neoplasms, with particular focus on measurable residual disease detection.. ...
Analysis of circulating cell-free DNA (cfDNA) is a promising approach for non-invasive detection of human cancer. The approach has wide-spread applications including early detection of disease in asymptomatic individuals, residual disease detection and disease monitoring. A challenge for the clinical utilization of cfDNA is the small fragment size of cfDNA and the limited amount of cfDNA present in blood. For detection of circulating tumor DNA (ctDNA) highly sensitive methods for cfDNA detection e.g. targeted sequencing and digital droplet PCR (ddPCR) target tumor specific mutations or DNA methylation alterations. Detection of methylation-based biomarkers requires that cfDNA is bisulfite converted prior to biomarker detection, which is known to be associated with some loss of cfDNA. Yet, surprisingly few efforts have focused on ensuring high cfDNA bisulfite conversion (BSC) efficiency and -recovery, and few commercial kits are especially designed for this purpose. In this study we aimed to find ...
Thank you for your interest in spreading the word about Haematologica.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
Paperity: the 1st multidisciplinary aggregator of Open Access journals & papers. Free fulltext PDF articles from hundreds of disciplines, all in one place
Research Hypothesis: Treatment with nivolumab will extend disease-free survival, compared with placebo, as adjuvant therapy in all randomized patients and in patients with PD-Ll expressing tumors (membranous staining in (great or equal to 1%) with high risk residual disease at radical resection of invasive urothelial carcinoma (IUC). Co-Primary Objectives: To compare the disease free survival (DFS) for nivolumab versus placebo in: Subjects with tumors expressing PD-LI (great or equal to 1% membranous staining in tumor cells) and; All randomized subjects. Secondary Objectives: To compare non-urothelial tract recurrence free survival (NUTRFS) for nivolumab versus placebo in subjects with tumors expressing PD-LI (great or equal to 1% membranous staining in tumor cells) and all randomized subjects. To compare the disease specific survival (DSS) for nivolumab and placebo in subjects with tumors expressing PD-LI (great or equal to 1% membranous staining in tumor cells) and all randomized subjects. To ...
TY - JOUR. T1 - Carbohydrate biomarkers for future disease detection and treatment. AU - Cheng, Yunfeng. AU - Li, Minyong. AU - Wang, Shaoru. AU - Peng, Hanjing. AU - Reid, Suazette. AU - Ni, Nanting. AU - Fang, Hao. AU - Xu, Wenfang. AU - Wang, Binghe. PY - 2010/1/1. Y1 - 2010/1/1. N2 - Carbohydrates are considered as one of the most important classes of biomarkers for cell types, disease states, protein functions, and developmental states. Carbohydrate binders that can specifically recognize a carbohydrate biomarker can be used for developing novel types of site specific delivery methods and imaging agents. In this review, we present selected examples of important carbohydrate biomarkers and how they can be targeted for the development of therapeutic and diagnostic agents. Examples are arranged based on disease categories including (1) infectious diseases, (2) cancer, (3) inflammation and immune responses, (4) signal transduction, (5) stem cell transformation, (6) embryo development, and (7) ...
83 CR 41% 39%). knowledge revealed that early discontinuation and long-term cytopenias had been connected with an age group >65 years significantly.2 The improved tolerability of PCO allowed us to conserve the dosage intensity enabling the attainment of very similar results even with regards to CR seen in older people treated with FCR both in the CLL 8 and MDACC studies.1 9 It ought to be emphasized which the addition of ofatumumab using its capability to promote CDC allowed a substantial proportion of sufferers to achieve not just a high CR price but also a MRD bad CR. It really is tough to evaluate MRD outcomes among studies as methods period points and test sources differ broadly across studies. It is popular that MRD is an integral aspect for durable B and remission?ttcher et al. showed which the profound reduced amount of tumor download of treatment regimen symbolizes the main prognostic feature regardless.10 Inside our series we confirm the prognostic value of MRD level as PFS demonstrated ...
Ovarian cancer is the most deadly gynecological cancer because of late diagnosis, frequently with diffuse peritoneal metastases. Recent findings have shown that serous epithelial ovarian cancer has a narrow mutational spectrum with TP53 being the most frequently targeted when single genes are considered. It is, however, important to understand which pathways as a whole may be targeted for mutation. Previously published mutational data provided by the cancer genome atlas networks findings on ovarian cancer was searched for statistically significant enrichment of genes in pathways. These pathways were then searched in all patients to identify the spectrum of mutations. Statistical significance was further shown through in-silico permutations of exome sequences using empirically observed mutation rates. We detected mutations in the cell adhesion pathway genes in more than 89% of serous epithelial ovarian cancer patients. This level of near universal mutational targeting of the cell adhesion pathway,
Parkinsons Disease Detection with Gait Recognition using Soft Computing Techniques: 10.4018/978-1-4666-9530-6.ch014: Parkinsons disease is a degenerative disorder of the central nervous system which occurs as a result of dopamine loss, a chemical mediator that is
A retrospective cohort study assessed Residual Cancer Burden (RCB), a standardized measure of residual disease in pathologic resection specimens following neoadjuvant chemotherapy, which was found to be prognostic of long-term survival in which breast cancer phenotypes? ...
I have been a little slow about talking about my recent visit to see Dr. Barlogie for a few reasons. I knew when I left I was SCR(Stringent complete response), no M spike, good light chain numbers, and a clean MRI of my bone marrow. However, it has taken a lot longer than normal to find out about my MRD(Minimal Residual Disease) status, and if MRD positive what was my Gene Expression Profile (GEP). I have been waiting and they say the delay in the GEP is because they can not find enough myeloma cells to run the test. Now that is just outstanding. The OH CRAP part comes in because when I got home and looked at my MRI output which had just been released, it had stated the following ...
1. Patients must be 12-65 years of age at the time of randomization 2. Patients with one of the following hematological malignancies: Acute lymphoblastic leukemia (ALL) at one of the following stages: a. High risk first complete morphologic remission (CR1), defined as one or more of the following: - -- The presence of adverse cytogenetics or adverse molecular changes. Examples of adverse cytogenetics are t(4;11), t(9;22), t(1;19), MLL rearrangements t(11q23) or severe hypodiploid ALL - -- Extreme leukocytosis at diagnosis (WBC ,30,000/[MICRO-SYMBOL]l for B-ALL or ,100,000/[MICRO-SYMBOL]l for T-ALL) - -- Failure to achieve complete morphologic remission after first induction therapy - -- Evidence of minimal residual disease (MRD) at screening by flow cytometry or molecular testing - -- Slow response to induction therapy, as evidenced by peripheral blood leukemic blasts one week after start of induction, or ,10% leukemic blasts in bone marrow 2 weeks after start of induction - -- Age older than 30 ...
1141 Cladribine induces long term complete remission in hairy cell leukemia (HCL) patients, but does not clear minimal residual disease (MRD) according to high-sensitivity PCR assays. To quantify MRD in patients after anti-CD22 recombinant immunotoxin BL22 and other agents, we used a relative quantitative PCR (RQ-PCR) assay using a patient specific primer and probe for immunoglobulin heavy chain junction originated from HCL cells. Using this method, we were able to detect 1 Bonna 12 HCL cell in either 106 Jurkat cells or in 106 normal mononuclear cells. We studied 84 samples from 10 patients, taken before or after treatment with BL22 and other agents. Patient-specific RQ-PCR was much more sensitive than flow cytometry, which in turn was (as recently reported) more sensitive than PCR using consensus primers. RQ-PCR was positive in 62 (100%) out of 62 flow-positive samples in 10 patients, and in 20 (91%) out of 22 flow-negative samples in 6 patients. The relative level of MRD as quantified by ...
MRD in AML can be based on molecular methods (PCR targeting fusion genes, mutations or expression levels of appropriate genes) or on multicolour flow cytometry. In flow cytometric MRD analysis leukemia-associated immunophenotypes (LAIPs) are indentified at diagnosis and applied to follow-up samples. Earlier, with four to six colour combinations, patient-specific LAIPs were designed on the basis of antigen profiles at diagnosis. Our strategy with eight to ten colour flow cytometry is to apply four standard combinations (for granulocytes, monocytes, stem cells and aberrant markers, respectively). This strategy not only allows the identification of LAIPs but also the analysis of granulocytic and monocytic differentiation patterns. The combinations also contain markers to identify e.g. mast cells, plasmacytoid dendritic cells, basophils and plasma cells, which may contaminate the so called blast area in CD45/side scatter plots. We in Tampere have three-year experience of ten-colour flow cytometric ...
Cancer dormancy is a stage in tumor progression in which residual disease remains occult and asymptomatic for a prolonged period of time. Dormant tumor cells can be present as one of the earliest stages in tumor development, as well as a stage in micrometastases, and/or minimal residual disease left after an apparently successful treatment of the primary tumor. The general mechanisms that regulate the transition of disseminated tumor cells that have lain dormant into a proliferative state remain largely unknown. However, regulation of the growth from dormant tumor cells may be explained in part through the interaction of the tumor cell with its microenvironment, limitations in the blood supply, or an active immune system. An understanding of the regulatory machinery of these processes is essential for identifying early cancer biomarkers and could provide a rationale for the development of novel agents to target dormant tumor cells. This review focuses on the different signaling models ...
Leukemia, PCR, PH, Time, Tyrosine, Acute Lymphoblastic Leukemia, Cells, Children, Disease, Flow Cytometry, Gene, Gene Rearrangements, Kinetics, Lymphoblastic Leukemia, Measure, Methods, Minimal Residual Disease, RNA, Tcr Gene, Chronic Myeloid Leukemia
Under the header Oncology biocore offers a broad range of tumor-diagnostic tests for early diagnosis and follow-up of patients under therapy. biocore offers as well screening tests as quantitative test which are particularly suited to detect and follow up minimal residual disease (MRD). MRD is the name given to the small number of leukemic or solid tumor cells that remain in the patient during treatment or after treatment, when the patient is in remission (no symptoms or signs of disease). It is the major cause of relapse in cancer and leukemia. Particularly unique are the high-multiplex real-time PCR tests for the simultaneous determination of up to 30 different translocations in acute and chronic leukemias with only one test (HemaVision®, Q-Fusion). In addition to the diagnosis of leukemia, molecular markers of various carcinomas and sarcomas can also be used diagnostically. In addition to the MRD tests, the section also contains a variety of tests for the detection of somatic mutation, ...
Key Inclusion Criteria for the ALL Cohort - Relapsed or refractory B-precursor ALL defined as one of the following: - Primary refractory disease - Any relapse within 18 months after first diagnosis - Relapsed or refractory disease after 2 or more lines of systemic therapy - Relapsed or refractory disease after allogeneic transplant provided individual is at least 100 days from stem cell transplant at the time of enrollment - Disease burden defined as at least 1 of the following: - Morphological disease in the bone marrow (, 5% blasts) - Minimal/Measurable Residual Disease (MRD) positive (threshold 10^-4 by flow or Polymerase chain reaction (PCR)) - Individuals with Ph+ disease are eligible if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have relapsed/refractory disease despite treatment with at least 2 different TKIs - Age ≤ 21 years and weight ≥ 6 kg at the time of assent or consent per Institutional Review Board (IRB) guidelines - Note: Individuals with a ...
Minimal Residual Disease (MRD) is being increasingly recognized as a biomarker and potential surrogate endpoint for a number of hematologic malignancies. We at Invivoscribe are excited to share details about LymphoQuant® for use with our LymphoTrack® assays to assess sample quality, qualify sensitivities, and estimate disease burden.. LymphoTrack® Low Positive ...
One of the appealing aspects of treatment at Sloan Kettering is the promise of no transplant. According to them, in their experience, they do not believe a transplant is necessary when antibodies (3F8) are used for consolidation of minimal residual disease. I should point out that this is in direct contradiction to three large randomized phase 3 trials which showed that transplant increased event free survival by 11% or more (these trials did not include the use of antibody, however.) Regardless, when analyzing the toxicities of transplant it is easy to be swayed by the allure of not having to have a transplant and the hope of achieving the same desired result. It is very appealing. People evaluate the response - children appear to achieve remission in similar numbers - and then they evaluate the toxicity - it isnt a transplant. The problem with this type of thinking is that it misses some extremely important factors. First and foremost, it misses the point that you are giving up on the proven ...
CÉLKITŰZÉSEK - AIMS II. Elemeztük az összes remisszió (ORR) és a teljes remisszió (CR) elérésének és tartósságának (PFS) arányát RFC kezelés hatására az alábbi szempontok alapján (CR = áramláscytometriával MRD negatív) We analysed the rate of ORR, CR and PFS after RFC therapy (CR = MRD negative with flow cytometer) Points of view: ÉletkorAge NemGender Rai stádiumStadium (Rai) Előző kezelésekPrevious therapies CD38CD38 ZAP-70ZAP-70 CLL-FISHCLL-FISH
Due to its growing social impact, prodromal detection of Alzheimers disease is of paramount importance. Biomarkers based on Magnetic Resonance Imaging (MRI) are one of the most sought results in the
Health,... Number of diseases that can be diagnosed just after conception is dou... yearly. North Carolina couple among th... probe. ...CHARLOTTE N.C. Nov. 2 /- Dramatic progress in thedetec...,Infertility,Doctors:,Genetic,Disease,Detection,is,Skyrocketing,,Could,Reshape,Medicine,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Researchers are working on a blood test that could revolutionise the detection of early Alzheimers disease. It requires only a few drops of blood and is as effective
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
5 ng per mL, while 7 of Onilne patients (88) with a residual cancer volume 0. пп Page 153 ппFig. 40 Nikolaou PK, Seaber AV, Glisson RR, et al. 53.
unitsconverters.com helps in the conversion of different units of measurement like Sv to mrd through multiplicative conversion factors.
After involution residual telangiectasias can be treated with laser therapy. Congenital hemangioma can be distinguished from ... Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm that is locally aggressive but without metastatic potential. ... After regression RICH may cause a residual deformity, such as atrophic skin and subcutaneous tissue. It mainly affects the ... Other therapeutic options are embolization and pulsed-dye laser, which improves residual telangiectasias in RICH and in NICH. ...
... neoplasm recurrence, local MeSH C23.550.727.670 - neoplasm regression, spontaneous MeSH C23.550.727.700 - neoplasm, residual ... neoplasm circulating cells MeSH C23.550.727.650.830 - neoplasm seeding MeSH C23.550.727.650.895 - neoplasms, unknown primary ... neoplasm invasiveness MeSH C23.550.727.645.500 - leukemic infiltration MeSH C23.550.727.650 - neoplasm metastasis MeSH C23.550. ...
"2.3.3 Residual categories - 'Other' and 'Unspecified'". ICD-11 Reference Guide. Talk:ICD-11#Residual nodes are maroon-colored ... For instance, the blood cancers, including all forms of leukemia, are in the "Neoplasms" chapter, but they are also displayed ... In the ICD-11 Browser, residual nodes are displayed in a maroon color. Residual categories are not in the Foundation, and ... neoplasms, and developmental anomalies, which can occur in almost any part of the body. They each have their own chapters, but ...
Residual cyst iii. Paradental cyst and juvenile paradental cyst iv. Inflammatory collateral cyst B. Non-epithelial-lined cysts ... However, sometimes these masses are considered neoplasm: Keratocyst Calcifying odotogenic cyst According to the current (2005) ... Cystic ameloblastoma Long standing dentigerous cyst, odontogenic keratocyst, and residual cyst may have neoplastic potential ... Residual cyst Most cysts in the body are benign (dysfunctional) tumors, the result of plugged ducts or other natural body ...
C R Nichols; N A Heerema; C Palmer (1987). "Klinefelter's syndrome associated with mediastinal germ cell neoplasms". JCO. 5: ... Initial treatment with four courses of bleomycin, etoposide, and cisplatin, followed by surgical resection of any residual ... of all germ cell neoplasms. Syndromes associated with mediastinal germ cell tumors include Hematologic Neoplasia and ...
Radioactive iodine-131 is used in patients with papillary or follicular thyroid cancer for ablation of residual thyroid tissue ... Thyroid neoplasm is a neoplasm or tumor of the thyroid. It can be a benign tumor such as thyroid adenoma, or it can be a ... Thyroid neoplasm might be classified as benign or malignant.[citation needed] Thyroid adenoma is a benign neoplasm of the ... The first step in diagnosing a thyroid neoplasm is a physical exam of the neck area. If any abnormalities exist, a doctor needs ...
... ic neoplasmEdit. Examples of neoplastic cysts include: *Dermoid cyst. *Keratocystic odontogenic tumor ... Residual cyst. *Sebaceous cyst - sac below skin. *Skene's duct cyst, a paraurethral cyst ...
Saito K, Katsumata Y, Hirabuki T, Kato K, Yamanaka M (2007). "Fetus-in-fetu: parasite or neoplasm? A study of two cases". Fetal ... there is concern that residual undifferentiated stem cells could lead to teratoma formation in injected patients, and ... It can be confused with other small round cell neoplasms such as neuroblastoma, small cell carcinoma of hypercalcemic type, ... Saba, Luca; Acharya, U. Rajendra; Guerriero, Stefano; Suri, Jasjit S. (2014). Ovarian Neoplasm Imaging. Springer Science & ...
Worse prognostic factors include the presence of residual tumor at the margin of the resection specimen (R+), invasion of the ... "Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin". Advances in Anatomic ...
Reductions in the mass of the liver are possible, since most patients retain residual hepatic function that allows for the ... Adenomas, composed of heterogeneous neoplasms, may occur individually or in multiples. Estimates on the rate of conversion of a ...
After involution residual telangiectasias can be treated with laser therapy. Congenital hemangioma[edit]. Congenital hemangioma ... Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm that is locally aggressive but without metastatic potential. ... Other therapeutic options are embolization and pulsed-dye laser, which improves residual telangiectasias in RICH and in NICH. ... However, patients may require intervention during childhood, because 50% of IH leave residual fibrofatty tissue, redundant skin ...
... some have classified OKCs as benign neoplasms. The best evidence to suggest that this type of cyst is not a neoplasm is that it ... They can be mistaken for other cysts such as residual cysts or a dentigerous cyst if they occur over an unerupted tooth. ... killing any residual epithelial cells to a depth of 1-2mm. Used with care near mandibular canal and the neurovascular bundle ... Odontogenic Keratocyst underwent the reclassification as it is no longer considered a neoplasm due to a lack of quality ...
Neoplasms III D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism ... I84.6) Residual haemorrhoidal skin tags. *(I85) Oesophageal varices. *(I86) Varicose veins of other sites *(I86.0) Sublingual ...
... or disseminated mucinous neoplasm of the appendix. These procedures can be 8-10 hours long and carry a significant rate of ... importantly noting that residual tumor mass size (. ...
Progression of EIN to carcinoma, effectively a conversion from a benign neoplasm to a malignant neoplasm, is accomplished ... Some cases of EIN are first detected as residual premalignant disease in women who already have carcinoma, whereas other EIN ...
The location could prohibit access to the neoplasm and lead to incomplete or no resection at all. Left unattended, these tumors ... In cases of progressive/recurrent disease or when maximal surgical removal has been achieved but some residual tumor remains, ... The complaints may vary depending on the location and size of the neoplasm. The most common symptoms are associated with ... surgeons may decide to monitor the neoplasm's evolution and postpone surgical intervention for some time. However, total ...
In rare cases, chemotherapy may be used for recurrent or residual tumors. Overall, the outcome is good, although it is quite ... Definitions: A rare, biphasic, neuroblastic, and pigmented epithelial neoplasm of craniofacial sites, usually involving the ...
The normal architecture of a lymph node is partially effaced by a polymorphous infiltrate and residual follicles are commonly ... and NK-cell neoplasms: Angioimmunoblastic T-cell lymphoma". WHO Classification of Tumours of Haematopoietic and Lymphoid ...
... often mistaking astroblastoma with glial neoplasms, high-grade astrocytes, and embryonal neoplasms. However, the "bubbly" ... However, since residual tissue size is a large determinant for profiling recurrence, it is almost never the case that a low- ... Furthermore, the absence of chromosome function in 9q, 10, and X were not observed in other types of neoplasms, such as an ... Neoplasm Neuroepithelial cell Astrocytes Glial cells Brain cancer Astroblastoma at Curlie Unal, Ekrem, and Yavuz Koksal. " ...
Residual redness may be noted and can be improved with laser therapy, most commonly PDL. Ablative fractional resurfacing may be ... Vascular anomalies are divided into vascular tumors/neoplasms which include infantile hemangiomas, and vascular malformations ... Surgery may also be useful for removal of residual fibrofatty tissue (following hemangioma involution) and reconstruction of ...
Sertoli-Leydig cell tumour is part of the sex cord-stromal tumour group of ovarian neoplasms. These tumors produce both sertoli ... Sertoli cells also act as phagocytes, consuming the residual cytoplasm during spermatogenesis. Translocation of cells from the ...
Other neoplasms (or sources of inflammation) should therefore be considered in known or suspected LAM cases in which FDG-PET ... The average residual volume was 125% of predicted when measured by plethysmography, but was only 103% of predicted determined ... Reduction in DLCO and increase in residual volume are generally considered to be LAM's earliest physiologic manifestations.[ ...
Variability of the phenotype, associated with residual ubiquitin ligase activity in some patients, has also been attributed to ... a neoplasm, or tumor composed of glial cells) on a lobe of the pituitary gland, as well congenital underdevelopment of the ... Continuing homozygous mutations, one converts guanine to adenine, in intron 26 resulting in residual normal protein production ... but mild symptoms are also common in missense mutations in at least one of the two UBR1 copies with possible residual activity ...
Compared to neoplasm, hematomas show higher density in pre-contrast scans with solid components tending to locate peripherally ... It treats the hemorrhage by adrenal repair or adrenalectomy, depending on the extent of injury, the viability of residual ... such as adrenal neoplasm, adrenocortical carcinomas, and pheochromocytomas. Hematomas have solid adrenal nodules, size of which ...
... is the study of brain and spinal cord neoplasms, many of which are (at least eventually) very dangerous and life ... With modern neurosurgical techniques, most patients with extra-axial brain tumors are cured with minimal residual neurologic ... and the specific type of malignant brain neoplasm. Surgery may in some cases be curative, but, as a general rule, malignant ... Meningioma assecond malignant neoplasm after oncological treatment during childhood. 188, 438-441. Retrieved from [1][dead link ...
Modified visual output that includes large print and/or clear simple graphics can be of benefit to users with some residual ... Malignant neoplasms of the brain and nervous system (1.5%) Retinal detachment (1.4%) Cataracts are the congenital and pediatric ... Some people who fall into this category can use their considerable residual vision - their remaining sight - to complete daily ...
Vermeeren A (2004). "Residual effects of hypnotics: epidemiology and clinical implications". CNS Drugs. 18 (5): 297-328. doi: ... These were cancers of the brain, lung, bowel, breast, and bladder, and other neoplasms. Not only are benzodiazepines associated ... Borland RG, Nicholson AN (February 1975). "Comparison of the residual effects of two benzodiazepines (nitrazepam and flurazepam ... Residual "hangover" effects after nighttime administration of nitrazepam such as sleepiness, impaired psychomotor and cognitive ...
Approximately 99% of lung cancers are carcinoma, a term that indicates that the malignant neoplasm is composed of, or descended ... TRT serves to increase the probability of total eradication of residual locoregional disease, while PCI aims to eliminate any ... Other experts recommend resection for residual masses of NSCLC components after complete local tumor response to chemotherapy ... April 2008). "Genetic alterations in combined neuroendocrine neoplasms of the lung". Mod. Pathol. 21 (4): 414-22. doi:10.1038/ ...
Large residual masses found after chemotherapy may require surgical resection. Second-line treatment is the same as for ... It is a malignant neoplasm and is one of the most treatable and curable cancers, with a survival rate above 95% if discovered ...
Radioactive iodine-131 is used in people with papillary or follicular thyroid cancer for ablation of residual thyroid tissue ... Newly reclassified variant: noninvasive follicular thyroid neoplasm with papillary-like nuclear features is considered an ...
Modified visual output that includes large print and/or clear simple graphics can be of benefit to users with some residual ... Malignant neoplasms of the brain and nervous system (1.5%). *Retinal detachment (1.4%) ... Some people who fall into this category can use their considerable residual vision - their remaining sight - to complete daily ...
F1x.7) Residual and late-onset psychotic disorder. *(F1x.8) other mental and behavioural disorder ... Neoplasms III D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism ...
Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... be avoided by delivering the radiation more precisely to the targeted tissues leading to immediate sterilization of residual ...
These studies suppose that cancers happen from residual tissue radiation damage caused by the 131I, and should appear mostly ... "Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative ...
Nevertheless, residual T lymphopoiesis continues throughout adult life. In children, the thymus is pinkish-gray, soft, and ... ISBN 0-7020-2606-9. Huete-Garin, A.; S.S. Sagel (2005). "Chapter 6: "Mediastinum", Thymic Neoplasm". In J.K.T. Lee; S.S. Sagel ...
Kill any residual cell that was not killed by remission induction and intensification regimens *Can sometimes start immediately ... "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): ... Minimal residual disease. *Genetic disorders, such as Down syndrome, and other chromosomal abnormalities (aneuoploidy and ... Minimal residual disease Positive at 3 - 6 months Negative at 1 month (children) or 3 months (adults) ...
As a result, residual CpG islands are created in areas where methylation is rare, and CpG sites stick (or where C to T mutation ... see malignant neoplasms). Thus, CpG island hyper/hypo-methylation in the promoters of DNA repair genes are likely central to ...
Residual postinflammatory hyperpigmentation has been reported in association with OLP, manifesting as brown to black ... Salivary gland neoplasms *Benign: Basal cell adenoma. *Canalicular adenoma. *Ductal papilloma. *Monomorphic adenoma ...
Rohsenow DJ, Howland J (June 2010). "The role of beverage congeners in hangover and other residual effects of alcohol ... McGregor NR (November 2007). "Pueraria lobata (Kudzu root) hangover remedies and acetaldehyde-associated neoplasm risk". ... may predispose subjects to an increased risk of acetaldehyde-related neoplasm and pathology. ... Pueraria lobata appears to be ... congeners may potentially aggravate hangover and other residual effects to some extent. Congeners include substances such as ...
Residual lead in soil contributes to lead exposure in urban areas.[12] It has been thought that the more polluted an area is ... neoplasms of the central nervous system, emotional and behavior disorders, and intellectual disability.[23] ...
Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... be avoided by delivering the radiation more precisely to the targeted tissues leading to immediate sterilization of residual ... genetics and prevention of secondary neoplasms in adult cancer survivors". Nature Reviews Clinical Oncology. 10 (5): 289-301. ...
This re-enrichment recovery of the residual uranium-235 is now in practice in some parts of the world; e.g. in 1996 over 6000 ... found no consistent evidence of excess risks of neoplasms that could have some link to DU, and that "[t]he overall incidence of ...
անգիոմա, անոթային ուռուցք, cardiovascular organ benign neoplasm?[1] և բարորակ ուռուցք ըստ բջջային տեսակի[1]. ... growth pattern and residual lesions»։ Plastic and Reconstructive Surgery 127 (4): 1643-1648։ ISSN 1529-4242։ PMID 21460670։ doi ...
Nervous tissue tumors/NS neoplasm/Neuroectodermal tumor (ICD-O 9350-9589) (C70-C72, D32-D33, 191-192/225) ... and use of monoclonal antibodies and retinoids to treat minimal residual disease continue to be examined. Recent phase III ...
Wang SF, Lo WO «Benign neoplasm of kidney: Angiomyolipoma» (en anglès). J Med Ultrasound, 2018 Jul-Set; 26 (3), pp: 119-122. ... Eliminant productes residuals del metabolisme a través de l'excreció d'orina. *Regulant el volum dels fluids extracel·lulars, ...
Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are (at least eventually) very dangerous and life ... With modern neurosurgical techniques, most patients with extra-axial brain tumors are cured with minimal residual neurologic ... and the specific type of malignant brain neoplasm. Surgery may in some cases be curative, but, as a general rule, malignant ... Meningioma assecond malignant neoplasm after oncological treatment during childhood. 188, 438-441. Retrieved from http://www. ...
Recurrence in the residual cervix is very rare if the cancer has been cleared with the trachelectomy. Yet, women are ... Myung SK, Ju W, Kim SC, Kim H (October 2011). "Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: a ...
Feb 2017). "Endonasal endoscopic reoperation for residual or recurrent craniopharyngiomas". J Neurosurg. 126 (2): 418-430. doi: ... usually suprasellar neoplasm, which may be cystic, that develops from nests of epithelium derived from Rathke's pouch. Rathke's ... it remains unclear as to whether all patients with residual tumour should receive immediate or differed at relapse radiotherapy ... with radical surgery have prompted to adopt a combined strategy of conservative surgery and radiation therapy to residual tumor ...
Often, since facial neoplasms have such an intimate relationship with the facial nerve, removing tumors in this region becomes ... and reduce residual symptoms in case of incomplete recovery. However, for facial palsy caused by Lyme disease, corticosteroids ... While this will inevitably lead to heightened paralysis, safe removal of a malignant neoplasm is worth the often treatable ... Common culprits are facial neuromas, congenital cholesteatomas, hemangiomas, acoustic neuromas, parotid gland neoplasms, or ...
May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. ... to reach complete remission Early relapse of ALL Minimal residual disease Genetic disorders, such as Down syndrome, and other ...
ISBN 0-7817-5007-5. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... "Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori ...
Its expression is also increased in a wide range of other malignant neoplasms. Factor X (F10) is frequently expressed in normal ... Usually, the respiratory system shows signs of healing within 3 weeks of infection, however, residual lesions, inflammation, or ... It is also overexpressed in some cell lines originating from various malignant neoplasms. Thus, it is highly expressed in ... Some of these proteases are overexpressed in malignant neoplasms. For example, transmembrane serine protease 2 (TMPRSS2), which ...
May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. ... multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual ... It is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation called the Philadelphia ... classification of the myeloid neoplasms". Blood. 100 (7): 2292-302. doi:10.1182/blood-2002-04-1199. PMID 12239137. S2CID ...
Frick J, Marberger H, Swoboda HP (May 1971). "[Hormone therapy of prostatic neoplasms]". Urologe (in German). 10 (3): 117-9. ... but the residual current. Appetite enhancement induced by megestrol acetate might be partly due to the inhibition of these Ca2+ ...
... Karl ... Karl Haslam and Stephen E. Langabeer, "Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current ...
Investigational Drugs with Clinical Trials for: Neoplasm, Residual. ➠ Get the DrugPatentWatch Daily Briefing. » See Plans and ...
Build: Fri Apr 12 22:16:45 EDT 2019 (commit: 82eed56). National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-435-0888. ...
volume of residual tumor. *percentage of tumor removed. *(and 9 more...). 700. All. 18 Years to 80 Years (Adult, Senior). ... 46 Studies found for: Recruiting, Not yet recruiting, Available Studies , Pituitary Neoplasms ...
Ovarian Neoplasms. Neoplasms. Endocrine Gland Neoplasms. Neoplasms by Site. Ovarian Diseases. Adnexal Diseases. Genital ... Diaphragmatic Resection And Gynecological Ovarian Neoplasm (DRAGON). The safety and scientific validity of this study is the ... Residual thoracic disease after surgery. *Residual diaphragmatic disease after surgery. Contacts and Locations ...
Colonic Neoplasms. Neoplasm, Residual. Colorectal Neoplasms. Intestinal Neoplasms. Gastrointestinal Neoplasms. Digestive System ... Neoplasms by Site. Neoplasms. Digestive System Diseases. Gastrointestinal Diseases. Colonic Diseases. Intestinal Diseases. ... minimal residual disease. cancer recurrence. epidural. morphine. piritramide. colon. cancer. circulating cancer cells. colon ... Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery. The ...
Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy ... Neoplasm Metastasis * Neoplasm Staging * Neoplasm, Residual * Peripheral Nervous System Diseases / chemically induced ... Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/ ... Conclusions: Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of ...
Validation of a Method to Search Residual Disease in Auto-cryopreserved Ovarian Tissues (VMRDO). The safety and scientific ... Amiot C, Angelot-Delettre F, Zver T, Alvergnas-Vieille M, Saas P, Garnache-Ottou F, Roux C. Minimal residual disease detection ... Zver T, Alvergnas-Vieille M, Garnache-Ottou F, Ferrand C, Roux C, Amiot C. Minimal residual disease detection in cryopreserved ... Validation of a Method to Search Residual Disease in Auto-cryopreserved Ovarian Tissues. ...
Neoplasm Recurrence, Local / diagnosis* * Neoplasm, Residual * Radiotherapy / adverse effects* * Sensitivity and Specificity ... Results: The patient series included five cases of DN and seven recurrent/residual tumor cases, based on histology. The MRS ... Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed ... Subsequent histological studies identified the brain lesion as DN or recurrent/residual tumor. ...
16-05 775A DATE: September 6, 2018 REMANDED Entitlement to service connection for residuals of neoplasm of the testis is ... back injury residuals of lung cancer residuals of malaria residuals of neoplasm of the testis residuals of procedures residuals ... residuals of back injury residuals of bladder cancer residuals of cancer Residuals of cerebrovascular accident (CVA) residuals ... toe of the right foot residual scars due to IHD residual SFW residuals of a back injury residuals of a cold injury residuals of ...
To investigate the frequency of residual cortex and the effectiveness of removal of residual cortex in the fovea during ... Neoplasm, Residual. Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written ... To investigate the frequency of residual cortex and the effectiveness of removal of residual cortex in the fovea during ... INSPIRATORY CAPACITY plus FUNCTIONAL RESIDUAL CAPACITY; TIDAL VOLUME plus INSPIRATORY RESERVE VOLUME plus functional residual ...
Neoplasm, Residual. Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written ... Summary of "Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.". ... Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.. 08:00 EDT ... Home » Topics » Womens Health » Research » Estimation of the individual residual risk of cervical cancer after vaccination ...
Neoplasm, Residual. Predictive Value of Tests. Retrospective Studies. Uterine Cervical Neoplasms / pathology*. ... Of patients with positive margins, 55% (12/22) were diagnosed with residual or recurrent disease, including 3 patients ... Thirteen percent of patients with negative conization margins (6/46) were diagnosed with residual or recurrent disease, ... women still face a risk of residual, recurrent, or invasive disease.. ...
Residual disease (RD) after induction chemotherapy may predict clinical outcome in acute myeloid leukemia (AML). In the present ... METHODS: Fifty patient samples comprising 46 AML and 4 other myeloid neoplasms were accrued for the study. They consisted of 19 ... Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia ... Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.. Diagn Pathol ...
NPM1 and Residual Disease. View Publications. 43. Myelodysplastic Syndromes. NPM1 and Myelodysplastic Syndromes. View ... The rs182123615 JAK2 variant was described in several contexts including myeloproliferative neoplasms and congenital ... Assessment of Minimal Residual Disease in Standard-Risk AML.. N Engl J Med. 2016; 374(5):422-33 [PubMed] Related Publications ... Minimal Residual Disease assessment of IDH1/2 mutations in Acute Myeloid Leukemia by LNA-RQ-PCR.. Tunis Med. 2016; 94(3):190-7 ...
Neoplasm, Residual / surgery. Neuroblastoma / complications, drug therapy*, surgery*. Neurologic Examination. Paraplegia / ... Spinal Neoplasms / complications, drug therapy*, surgery*. Survival Rate. Treatment Outcome. From MEDLINE®/PubMed®, a database ... The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A ...
Conditions: Acute Bilineal Leukemia; Minimal Residual Disease; Myelodysplastic/Myeloproliferative Neoplasm; Myelodysplastic/ ... The Role of New Technologies in Myeloproliferative Neoplasms. Conclusions The discovery of JAK2V617F mutation in BCR-ABL1- ... Myeloproliferative Neoplasm, Unclassifiable; Myeloproliferative Neoplasm; Recurrent Acute Biphenotypic Leukemia; Recurrent ... Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm; ...
Results were adjusted for residual inflation using genomic control.36. In regions with genome-wide significant associations, we ... JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41(4):446-449. ... Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2014;55(3):595-600. ... Focus on the epigenome in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2013;2013(1):538-544. ...
Patients have measurable residual or progressive lesions after surgery.. - Patients who have had prior WBRT and/or SRS are ... Patients have measurable residual or progressive lesions after surgery.. *Patients who have had prior WBRT and/or SRS are ...
Residual Neoplasm 11/2006 - 10/2006. 2. Wounds and Injuries (Trauma) 09/2006 - 05/2004. ... Breast Neoplasms (Breast Cancer). 11/2015. Response to preoperative endocrine therapy in breast cancer patients can alter ...
Neoplasm, Residual. .map{width:100%;height:300px;margin-bottom:15px}. Name. Location. ... FLT3-ITD or MLL-PTD) and low minimal residual disease levels after consolidation. (MRD. sibling.. - The remaining patients ... Risk Adapted Treatment for Primary AML in Adults, Based on Genetics and Minimal Residual Disease (MRD) in Patients up to the ... Risk Adapted Treatment for Primary AML in Adults, Based on Genetics and Minimal Residual Disease (MRD) in Patients up to the ...
Testing for minimal residual disease in cell samples from patients with acute lymphoblastic leukemia may help doctors plan ... Neoplasm, Residual. .map{width:100%;height:300px;margin-bottom:15px}. Name. Location. ... To define the ability of this technology to reclassify patients as minimal residual. disease (MRD) positive at Day 29 of ... Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region to Identify Previously Undetectable Minimal Residual ...
Simple hysterectomy for residual cervical intraepithelial neoplasm. J Low Genit Tract Dis. 2018;22(2):126-8.PubMedCrossRef ... Risk of anal cancer in women with a human papillomavirus-related gynecological neoplasm. J Low Genit Tract Dis. 2018;22(3):225- ...
7915 Neoplasm, benign, any specified part of the endocrine system:. Rate as residuals of endocrine dysfunction.. ... DC 7914: Neoplasm, Malignant, Any Specified Part of the Endocrine System. *DC 7915: Neoplasm, Benign, Any Specified Part of the ... DC 7915: Neoplasm, Benign, Any Specified Part of the Endocrine System. VA proposes to retain the existing direction to rate ... 7914 Neoplasm, malignant, any specified part of the endocrine system. 100. Note: A rating of 100 percent shall continue beyond ...
Rate the residuals of partial laryngectomy as laryngitis (DC 6516), aphonia (DC 6519), or stenosis of larynx (DC 6520). ... 6820 Neoplasms, benign, any specified part of respiratory system. Evaluate using an appropriate respiratory analogy. ... Evaluate other residuals following pulmonary embolism under the most appropriate diagnostic code, such as chronic bronchitis ( ... 6819 Neoplasms, malignant, any specified part of respiratory system exclusive of skin growths. 100 ...
B. CNS neoplasm. C. Chronic bronchitis (no). D. Chronic opiate use (wrong). E. Myasthenia gravis (yes???). F. Obesity ... Her residual volume is within reference range. Which is the most likely underlying cause of this patients condition?. A. alpha ...
Erratum to: Biliary Intraductal Papillary Mucinous Neoplasm: the "Thread Sign". Review Article ... Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. Journal of ... Residual Disease Predicts Outcomes after Definitive Resection for Incidental Gallbladder Cancer. Journal of the American ... Predicting Residual Disease in Incidental Gallbladder Cancer: Risk Stratification for Modified Treatment Strategies. ...
Myeloma survival: Post-transplant response and minimal residual disease. Take Quiz. Multiple myeloma outcomes: Lower- & higher- ... AUA Guideline: Follow-up for clinically localized renal neoplasms. Take Quiz. ATA Guidelines: Surgery for thyroid cancer. Take ... AUA Guideline: Follow-up for clinically localized renal neoplasms. Take Quiz. ATA Guidelines: Surgery for thyroid cancer. Take ... AUA Guideline: Follow-up for clinically localized renal neoplasms. Take Quiz. Clinical features and pathology of bladder cancer ...
Neoplasia means "new growth" = Neoplasm = Tumor. "A neoplasm is an abnormal mass of tissue, the growth of which exceeds and is ... Detection of minimal residual disease (e.g., ALL, CML).. Diagnosis of a hereditary predisposition to cancer (e.g. BRCA1 or ... Prognosis of malignant neoplasms:. • Specific chromosomal abnormalities can be associated with a better or worse prognosis in ... Define grading and staging of malignant neoplasms in just a few sentences. Describe what T,N,M refer to in the AJCC staging ...
Estimating YLD for residual diseases. *5 Disease specific methods *Blood and metabolic disorders ... Cancer and other neoplasms. *Hearing and vision disorders. *Infant and congenital conditions ...
  • We undertook a pilot study to assess the ability of proton magnetic resonance spectroscopy (1H MRS) to differentiate prospectively between DN or recurrent/residual tumor in a series of children treated for primary brain tumors with high-dose irradiation. (nih.gov)
  • Subsequent histological studies identified the brain lesion as DN or recurrent/residual tumor. (nih.gov)
  • The patient series included five cases of DN and seven recurrent/residual tumor cases, based on histology. (nih.gov)
  • Purpose This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. (her2support.org)
  • The spindle epithelial tumor with thymus-like element (SETTLE) is a very rare neoplasm related to the thyroid of young individuals. (omicsonline.org)
  • In 1991, Chan and Rosai unified the concept of SETTLE when they described 8 neoplasms situated in the neck and thyroid of children and young adults, previously diagnosed as malignant teratoma of the thyroid, thyroid spindle cell tumor with mucous cysts or thyroid thymoma. (omicsonline.org)
  • One year after the initial resection, a second resection was performed for residual/recurrent tumor adjacent to the optic nerve. (thefreelibrary.com)
  • High expression of EGFL7 (grade 2 or 3) was significantly correlated with pathologic type, differentiation, stage, residual tumor after debulking surgery, lymphovascular space involvement, lymph node metastasis, high cancer antigen 125, peritoneal cytology, and ascites. (nih.gov)
  • A brain neoplasm , commonly known as a brain tumor, is a collection of abnormal cells originating within the brain tissue. (wisegeek.com)
  • When a tumor forms within the brain in the presence of an existing cancer in another part of the body, it is considered to have metastasized from the original cancer to become a secondary brain neoplasm and is malignant. (wisegeek.com)
  • Chemo and radiation therapies are generally administered to target and eliminate any residual malignancy, such as a remaining portion of the tumor. (wisegeek.com)
  • 7 , 13 , 14 The aim of this study was to evaluate the role of diffusion-weighted MR imaging in differentiating residual or recurrent head and neck tumor from postoperative or postradiation changes. (ajnr.org)
  • mean age, 58 years) after surgical resection and/or radiation therapy who were suspected to have residual or recurrent tumor of the head and neck. (ajnr.org)
  • Twenty patients with high-grade gliomas were prospectively studied by pre- and postoperative transcranial color-coded real-time sonography (TCCS) and CT, to determine the sensitivity of TCCS in the identification of residual tumor and tumor regrowth. (uni-regensburg.de)
  • Histological findings of intraoperative biopsy specimens showed that hyperechogenic areas adjacent to the resection cavity always contained residual tumor tissue. (uni-regensburg.de)
  • In 12 patients, postoperative CT revealed contrast enhancement at the resection margin, indicating residual tumor. (uni-regensburg.de)
  • TCCS and histological findings indicated residual tumor in seven of these eight patients. (uni-regensburg.de)
  • From these data we conclude that the sensitivity of TCCS in detection of residual tumor and tumor regrowth seems to be superior to CT. (uni-regensburg.de)
  • Although they are the most common intramedullary glial tumor in adults, ependymomas are the second most common spinal cord neoplasms in children. (appliedradiology.com)
  • Although CT is not the best modality for characterizing neoplasms and mapping extent of disease, CT can help define the site of origin, depict bony remodeling vs. bony destruction, and detect internal calcifications and tumor matrix. (appliedradiology.com)
  • Although complete resection of the tumor is the principle treatment, SPN enucleation (EN) has been reported to be effective in children. (frontiersin.org)
  • There was no residual giant cell tumor identified in the entirely submitted sample. (rochester.edu)
  • Giant cell tumor of bone treated with denosumab is a diagnostic pitfall with morphologic overlap with numerous benign fibro-osseous and fibrohistiocytic neoplasms. (rochester.edu)
  • Thyroid neoplasm is a neoplasm or tumor of the thyroid. (wikipedia.org)
  • It can be a benign tumor such as thyroid adenoma, or it can be a malignant neoplasm (thyroid cancer), such as papillary, follicular, medullary or anaplastic thyroid cancer. (wikipedia.org)
  • Karl Haslam and Stephen E. Langabeer, "Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches," BioMed Research International , vol. 2016, Article ID 7241591, 6 pages, 2016. (hindawi.com)
  • The aim of this study is to compare the effects of three types of perioperative analgesia on the number of circulating cancer cells (representing minimal residual disease ) following radical colon cancer surgery. (clinicaltrials.gov)
  • In the early postoperative period, a relationship between metastasis development and the number of circulating cancer cells representing minimal residual disease has been shown. (clinicaltrials.gov)
  • Risk Adapted Treatment for Primary AML in Adults, Based on Genetics and Minimal Residual Disease (MRD) in Patients up to the Age of 70 Years. (knowcancer.com)
  • To define the ability of this technology to reclassify patients as minimal residual disease (MRD) positive at Day 29 of induction. (knowcancer.com)
  • The in vitro amplification of genomic or complementary deoxyribonucleic acid (cDNA) target sequences by polymerase chain reaction [1] has opened new avenues toward the detection of minimal residual leukemic cells at frequencies of 1:10000 to 1:1000000. (springer.com)
  • Hansen-Hagge TE, Yokota S, Bartram CR (1989) Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor δ chain sequences. (springer.com)
  • Bartram CR, Janssen JWG, Schmidtberger M, Lyons J, Arnold R (1989) Minimal residual leukaemia in chronic myeloid leukaemia after T-cell depleted bone marrow transplantation. (springer.com)
  • A combinatorial approach using old agents with anticancer properties together with novel JAK1/2 inhibitors may open a new era for patients with MPNs, the outlook not only being "minimal residual disease" and potential cure but also a marked improvement in inflammation-mediated comorbidities. (hindawi.com)
  • Clinicians expect pathological guidance not only with accurate diagnosis, but also about disease progression, minimal residual disease, disease susceptibility to a particular therapy, effects of prior therapy on prognosis and subsequent therapy etc. (schweitzer-online.de)
  • Detection of Minimal Residual Disease. (schweitzer-online.de)
  • also named minimal residual disease) detected in AML patients with hematological complete remission after treatment has been suggested as a powerful prognostic indicator ( 4 , 5 ). (frontiersin.org)
  • Targeting minimal residual disease: a path to cure? (harvard.edu)
  • These data identify a novel PYK2-mediated survival pathway in MM cells and MM cancer stem cells within the context of microenvironmental cues, providing preclinical support for the use of the clinical stage FAK/PYK2 inhibitors for treatment of MM, especially in a minimal residual disease setting. (elsevier.com)
  • To evaluate the association between histologic response and minimal residual disease (MRD) in gastric bipsies of MALT lymphomas, associated or not to H. pylori infection. (imim.es)
  • He is specifically interested in studies of minimal residual disease (MRD) as detected by flow cytometry and its effect on prognosis. (hopkinsmedicine.org)
  • Over the past 15 years, Dr. Borowitz's lab has studied samples of more than 10,000 patients enrolled in Children's Oncology Group trials for acute lymphoid leukemia for the presence of minimal residual disease. (hopkinsmedicine.org)
  • This trial follows the recent opening of trials with SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed/refractory acute myeloid leukemia (AML) and in patients with AML in first complete response (CR) with minimal residual disease (MRD). (cnbc.com)
  • Additional clinical trials with SL-401 are currently open in patients with AML who are in first complete remission (CR) with minimal residual disease (MRD), which is associated with a high relapse rate, and several uncommon, stem cell-derived myeloproliferative disorders. (cnbc.com)
  • Is further testing recommended after myeloproliferative neoplasm diagnosis is made? (arupconsult.com)
  • Clinically, patients often present with a chronic myeloproliferative neoplasm with eosinophilia and an increased risk of transformation to acute leukemia. (jnccn.org)
  • Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. (springermedizin.de)
  • Residual Disease Predicts Outcomes after Definitive Resection for Incidental Gallbladder Cancer. (springermedizin.de)
  • Survival following resection of IPMNs without invasive cancer (regardless of degree of dyplasia) is good, but recurrent disease in the residual pancreas suggests that long-term surveillance is critical. (uptodate.com)
  • The purpose of this report was to review the results of stereotactic radiosurgery in the management of patients with residual neurocytomas after initial resection or biopsy procedures. (thejns.org)
  • Aetna considers pancreaticoduodenectomy (also known as Whipple resection) medically necessary for the treatment of intraductal papillary mucinous neoplasm of the pancreas (IPMN) with high-grade dysplasia or invasive cancer. (aetna.com)
  • The EN group had one case of recurrence at the resection site. (frontiersin.org)
  • A lack of residual NIR fluorescence after resection was closely correlated with a lack of residual enhancement on postoperative MRI (p = 0.007). (thejns.org)
  • Postresection residual fluorescence can be a powerful tool to evaluate extent of resection in conjunction with MRI, and it may guide decisions on brain metastasis management. (thejns.org)
  • A multicenter clinical trial with SL-401 is currently open and accruing patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and advanced acute myeloid leukemia (AML). (cnbc.com)
  • Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. (uptodate.com)
  • OBJECTIVE: To update the authors' experience with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. (uptodate.com)
  • Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma ( 1, 2 ). (aacrjournals.org)
  • had frozen section performed on the cyst wall intraoperatively, all confirming mucinous neoplasms. (who.int)
  • To determine if these genetic lesions appear in Drosophila tumors we have sequenced the genomes of 17 malignant neoplasms caused by mutations in l(3)mbt , brat , aurA , or lgl . (g3journal.org)
  • Many of these tumors are hyperplasias that present during larval development and eventually differentiate, but others behave as frankly malignant neoplasms that are refractory to differentiation signals, lethal to the host and immortal. (g3journal.org)
  • The question remains, however, as to the extent of GI in other samples of Ph tumors and, indeed, in different types of Drosophila malignant neoplasms. (g3journal.org)
  • The development of aromatase inhibitors (AIs) for the treatment of breast cancer potentially provides such a therapeutic alternative since AIs block the synthesis of estradiol, depriving the estrogen receptor of its ligand which promotes proliferation of both breast and endometrial malignant neoplasms. (scirp.org)
  • Solid pseudopapillary neoplasms (SPNs) are rare, low-grade, malignant neoplasms that can occur in pediatric patients. (frontiersin.org)
  • Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone. (nih.gov)
  • Follow-up imaging for residual disease and recurrence is often necessary, further favoring MRI over CT as the imaging modality of choice. (appliedradiology.com)
  • We conducted a genome-wide association study (GWAS) to identify novel predisposition alleles associated with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) and JAK2 V617F clonal hematopoiesis in the general population. (bloodjournal.org)
  • Although the JAK2 V617F (V617F) mutation is identified in almost all patients with polycythemia vera (PV) and ∼50% to 60% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF), 1 ⇓ ⇓ - 4 these BCR-ABL1 -negative myeloproliferative neoplasms (MPNs) exhibit a spectrum of phenotypes that cannot be explained by a single molecular abnormality. (bloodjournal.org)
  • Myeloproliferative neoplasms (MPNs) are a group of blood cancers that cause excess blood cell production in the bone marrow and often in the peripheral blood, and are characterized by clonal genetic changes. (arupconsult.com)
  • The diagnosis of myeloproliferative neoplasms (MPNs) requires a combination of CBC and peripheral smear examination, bone marrow histology, chromosome analysis, and molecular testing. (arupconsult.com)
  • Myeloproliferative neoplasms (MPNs) are frequently characterized by deregulated tyrosine kinase signaling, particularly pathways involving JAK2. (bloodjournal.org)
  • Furthermore, ROS have a major role in carcinogenesis and disease progression in the myeloproliferative neoplasms (MPNs), where the malignant clone itself produces excess of ROS thereby creating a vicious self-perpetuating circle in which ROS activate proinflammatory pathways (NF- κ B) which in turn create more ROS. (hindawi.com)
  • The Philadelphia negative chronic myeloproliferative neoplasms (MPNs) encompass essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). (hindawi.com)
  • Chronic myeloproliferative neoplasms (MPNs) are a group of related conditions characterized by the overproduction of cells from one or more myeloid lineages. (nih.gov)
  • Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. (nih.gov)
  • We conducted a phase 3, open-label trial involving patients with HER2-positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. (nih.gov)
  • Patients have measurable residual or progressive lesions after surgery. (pfizer.com)
  • Of patients with positive margins, 55% (12/22) were diagnosed with residual or recurrent disease, including 3 patients diagnosed with adenocarcinoma on hysterectomy. (biomedsearch.com)
  • Thirteen percent of patients with negative conization margins (6/46) were diagnosed with residual or recurrent disease, including 2 patients diagnosed with adenocarcinoma during follow-up. (biomedsearch.com)
  • Patients with a history of a renal neoplasm presenting with acute neurological signs or symptoms should undergo which of the following imaging studies? (mdedge.com)
  • Residual IPMN was identified at the neck or uncinate margin in 24% of patients with noninvasive IPMNs. (uptodate.com)
  • At present, the concepts of self and self-identity are largely unexplored in neuro-oncology, but we discuss this clinical population in order to highlight the need for further clinical evaluation of these phenomena among patients with brain neoplasm. (bioethics.net)
  • 4 , 5 ] For this reason, when treatment is indicated, systemic treatment must be considered for all patients with symptomatic plasma cell neoplasms. (cigna.com)
  • The clinically ideal time point and optimal approach for the assessment of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) are still inconclusive. (frontiersin.org)
  • Via the treatment modalities as exemplified by cytotoxic drugs or molecular targeted therapies, a high complete remission (CR) rate could be achieved, however, a substantial proportion of AML patients will relapse due to residual leukemic cells below the detection threshold of traditional morphologic methods. (frontiersin.org)
  • However, patients may require intervention during childhood, because 50% of IH leave residual fibrofatty tissue, redundant skin, or damaged structures after involution. (wikipedia.org)
  • Six patients had anatomical liver resections and seven patients had non anatomical liver resections of which two needed ablation of residual cyst wall. (who.int)
  • Many patients with SN neoplasms are initially imaged with computed tomography (CT), as the presenting symptoms often mimic inflammatory disease. (appliedradiology.com)
  • This study aimed to examine the feasibility and safety of EN by comparing it with conventional pancreatectomy (CP), and to present the indications for its use in pediatric patients. (frontiersin.org)
  • Of the 66 patients, 15 (22.7%) were treated with EN and 51 (77.3%) were treated with CP. (frontiersin.org)
  • Dinutuximab beta is a targeted immunotherapy approved by the European Medicines Agency (EMA) for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma with or without residual disease. (biospace.com)
  • citation needed] Radioactive iodine-131 is used in patients with papillary or follicular thyroid cancer for ablation of residual thyroid tissue after surgery and for the treatment of thyroid cancer. (wikipedia.org)
  • This case provides direct evidence to illustrate the clonal relationship of chronic phase and blast phase in myeloid neoplasms with FGFR1 rearrangement, and demonstrates that clonal cytogenetic evolution plays an important role in disease progression. (jnccn.org)
  • Fibroblast growth factor receptor 1 ( FGFR1 )-associated myeloid and lymphoid neoplasm, also known as 8p11 myeloproliferative syndrome , is a rare hematopoietic neoplasm molecularly characterized by reciprocal translocations involving FGFR1 and one of its multiple partner genes. (jnccn.org)
  • Chronic Myeloproliferative Neoplasms (Other Than Chronic Myeloid Leukemia). (schweitzer-online.de)
  • Lymphoid Neoplasms With "Benign" Clinical Course or Unclear Malignant Potential. (schweitzer-online.de)
  • While differentiating one neoplasm from another can be difficult, imaging can often help differentiate benign from malignant lesions. (appliedradiology.com)
  • Papillomas are the most frequently encountered benign epithelial neoplasms, and the inverted papilloma (IPap) is the most common subtype. (appliedradiology.com)
  • citation needed] Thyroid neoplasm might be classified as benign or malignant. (wikipedia.org)
  • citation needed] Thyroid adenoma is a benign neoplasm of the thyroid. (wikipedia.org)
  • What is the role of next generation sequencing in the diagnosis of myeloproliferative neoplasms? (arupconsult.com)
  • Diagnosis of pre cancer cells Endometrial intraepithelial neoplasm May. (cancer.org)
  • Parathyroid carcinoma is an extremely rare malignant endocrine neoplasm that is very challenging in its diagnosis as well as its treatment. (egms.de)
  • A novel diagnostic index based on peak areas for choline and creatine compounds may provide a simple discriminant for differentiating DN from recurrent or residual primary brain tumors. (nih.gov)
  • Germ cell tumors are a heterogeneous group of neoplasms derived from residual primordial tissue. (jimmunol.org)
  • The purpose of this work was to evaluate whether diffusion-weighted MR imaging can be used in differentiating residual or recurrent head and neck tumors from postoperative or postradiation changes. (ajnr.org)
  • Diffusion-weighted MR imaging with ADC measurement has promising results for differentiating residual or recurrent head and neck tumors from postoperative or postradiation changes. (ajnr.org)
  • 10 Promising results have also been achieved for differentiation between residual or recurrent tumors and postradiation or postsurgical changes in soft tissues 11 and the brain. (ajnr.org)
  • Spinal cord tumors account for only 0.5% to 1% of all central nervous system (CNS) neoplasms. (appliedradiology.com)
  • Although SN neoplasms are relatively uncommon compared to other head and neck tumors, radiologists are likely to encounter these lesions because of the frequency of sinus imaging. (appliedradiology.com)
  • 1 The histologic categories of neoplasms include epithelial lesions, soft tissue tumors, tumors of bone and cartilage, hematolymphoid tumors, neuroectodermal tumors, germ cells tumors and secondary tumors. (appliedradiology.com)
  • The complete WHO classification of SN tumors can be found online at http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb9/index.php. (appliedradiology.com)
  • There are several types of plasma cell neoplasms. (cigna.com)
  • In other cases of neoplastic pathologies, particularly in cases of acute leukemia, tissue cannot as yet be re-used due to the lack of any codified technique for evaluating residual disease (MRD). (clinicaltrials.gov)
  • The team has for two years been developing and validating a technique to look for residual disease in fragments of ovarian cortex in cases of acute leukemia. (clinicaltrials.gov)
  • Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. (bioportfolio.com)
  • Cancer treatment may offer some hope for longer survival, but residual neurocognitive alterations generally remain. (bioethics.net)
  • Revisiones en Cancer. (springermedizin.at)
  • Though most secondary neoplasms are known to be metastatic in nature, some may form in the presence of an undiagnosed cancer. (wisegeek.com)
  • Since the authors' 2001 report, the number of IPMNs resected at our institution has more than doubled, providing an opportunity to define the clinical features of this distinct neoplasm. (uptodate.com)
  • Gastroenteric neuroendocrine neoplasms (GE-NENs) display highly variable clinical behavior. (wiley.com)
  • NEW YORK, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the initiation of a clinical trial with SL-401 in four rare myeloproliferative neoplasms (MPN). (cnbc.com)
  • The Board cannot make a fully-informed decision on the issue of service connection for residuals of neoplasm of the testis because the VA examiner, who provided the January 2015 did not have a copy of the Veteran's surgical and pathology report, which was later provided by the Veteran. (va-claim.com)
  • To achieve a long term remission and survival, post-remission therapies should be administered not only based on pre-treatment parameters including age, cytogenetics, and a limited set of molecular genetic markers, but also on several post-treatment factors, among which the detection of residual disease is of utmost importance ( 2 , 3 ). (frontiersin.org)
  • Hematopoietic neoplasms with FGFR1 rearrangements are rare. (jnccn.org)
  • Neoplasms of hematopoietic and lymphoid origin can be characterized by the expression of various cell surface or cytoplasmic markers. (questdiagnostics.com)
  • What is a Brain Neoplasm? (wisegeek.com)
  • Despite the various manifestations associated with a brain neoplasm, the origins of its presentation generally fall under one of two categories. (wisegeek.com)
  • There is no known cause for the abnormal cell development associated with the formation of a primary brain neoplasm. (wisegeek.com)
  • Organs in the immediate area, including the pineal and pituitary glands, may also host the initial development of a primary brain neoplasm. (wisegeek.com)
  • Generally, individuals with a brain neoplasm will develop sensory dysfunction. (wisegeek.com)
  • Additional signs of a brain neoplasm may include impaired cognition , chronic nausea and vomiting , and persistent headache. (wisegeek.com)
  • When used to treat a brain neoplasm, side effects associated with radiation therapy are dependent on the application method and may include fatigue and inflammation at the administration site. (wisegeek.com)
  • BACKGROUND DATA: IPMNs are intraductal mucin-producing cystic neoplasms of the pancreas with clear malignant potential. (uptodate.com)
  • Biliary mucinous cystic neoplasms (BMCNs) are uncommon neoplastic septated intrahepatic cysts which are often incorrectly diagnosed and have the potential for malignant transformation. (who.int)
  • The first step in diagnosing a thyroid neoplasm is a physical exam of the neck area. (wikipedia.org)
  • Additionally, a biopsy by stereotactic needle may be taken to obtain a sample of the neoplasm and surrounding tissue for further analysis. (wisegeek.com)
  • It is also helpful for directing biopsy, evaluating response to therapy, and detecting residual or recurrent disease in the previously treated patient. (appliedradiology.com)
  • It is a lowgrade malignant neoplasm, with epithelial differentiation confirmed by immunohistochemical. (omicsonline.org)
  • pancreatic neoplasms (C25. (cdc.gov)
  • Compared with CP treatment, EN of SPNs in children has the disadvantages of prolonged fasting times and hospital stays to recover from moderate pancreatic fistulas. (frontiersin.org)
  • Solid pseudopapillary neoplasm (SPN) is a rare pancreatic disorder that was first introduced by Virginia Frantz in 1959 ( 1 , 2 ). (frontiersin.org)
  • This low-grade malignant neoplasm of the pancreas accounts for ~1-3% of all cases of pancreatic neoplasms, occurring mostly in young women ( 3 ). (frontiersin.org)
  • Generally, a primary neoplasm may form within the actual brain tissue or its supportive tissues, such as the meninges. (wisegeek.com)
  • however, residual carcinoma in situ was identified in the resected specimen. (aacrjournals.org)
  • The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. (biomedsearch.com)
  • High-risk neuroblastoma is an aggressive neoplasm and the most common childhood solid tumour that originates outside of the brain. (biospace.com)
  • Dr. Borowitz's research focuses on defining the complexity of hematologic neoplasms. (hopkinsmedicine.org)
  • Specifically, this technique allows for dose-dependent, transdural localization of neoplasms and improved sensitivity in neoplastic margin detection. (thejns.org)
  • and 3) four types of advanced high-risk myeloproliferative neoplasms (MPN), including systemic mastocytosis, advanced symptomatic hypereosinophilic disorder, myelofibrosis, and chronic myelomonocytic leukemia. (cnbc.com)
  • MALT lymphomas of the stomach are neoplasm associated to antigenic stimulation by chronic infection by H. pylori. (imim.es)
  • No significant associations were found with upper or lower respiratory infections, otitis media, any infectious diseases, neoplasms, sensory disorders, urgent and inpatient health services use, pediatric complex chronic conditions, or mortality. (bmj.com)
  • to treatment of high grade neoplasms, especially high grade lymphomas. (coursera.org)
  • CONCLUSIONS: Even with negative conization margins, women still face a risk of residual, recurrent, or invasive disease. (biomedsearch.com)
  • These data indicate that the same germ line variants endow individuals with a predisposition not only to MPN, but also to JAK2 V617F clonal hematopoiesis, a more common phenomenon that may foreshadow the development of an overt neoplasm. (bloodjournal.org)
  • The 46/1 JAK2 haplotype predisposes to V617F-positive myeloproliferative neoplasms, but the underlying mechanism is obscure. (bloodjournal.org)
  • JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. (nih.gov)
  • 90%, it was usually possible to read the residual haplotype (that is, the haplotype of the chromosome that had not acquired JAK2 V617F ) by the finding of allelic ratios between 0.1-0.4 (for example, cases E2433 and E2513). (nih.gov)